

Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables and Boxes

ablative procedures
in CIN management 190

abnormal fetal karyotype
as risk for RPL 133

abnormal menstrual bleeding 13–20 *see also* heavy menstrual bleeding (HMB)
background 13–14, **13**
case scenario 13

abnormal placentation
suspected
tests for 552–3

abnormal uterine bleeding (AUB)
defined 13
FIGO on 13

abortion
failed 26–7
induced 21–32 *see also* induced abortion
medical evaluation prior to 22
pregnancies ending in 89
spontaneous
incidence of 33

abuse
substance *see* substance abuse

acanthosis nigra (AN)
PCOS and 122–3, 122

acceleration
defined **498, 499, 499**
in FHR
physiology of 502

ACCP
on VTE prevention during pregnancy 359, 361

ACE inhibitors *see* angiotensin-converting enzyme (ACE)
inhibitors

acne
isotretinoin for 207
PCOS and 122, 122

ACOG *see* American College of Obstetricians and Gynecologists (ACOG)

ACOG/SMFM Obstetric Care Consensus 569

acquired cardiac disease 267–73

antepartum management of 268–9
case scenario 267–8
causes of 268
clinical questions 268–73

acquired valvular lesions
in pregnant women
causes of 268

Actim PROM 398

active labor
centimeter progression during 570
initiation of 570

active management of risk in pregnancy at term (AMORIPAT) 528

active management of third stage of labor (AMTSL) 569
benefits of 576–7, **576**
described 576–7, **576**
oxytocin in 576–9, **576**, 578 *see also* oxytocin, in AMTSL
TXA in 578

acupuncture
in endometriosis pain management 79
in HG management 228
in post-term pregnancy management 436

acute anemia
HMB and 15

acute glomerulonephritis
pre-eclampsia *vs.* **292**

acute phase arrest
diagnosis of 570, **570**

acyclovir
for recurrent HSV infection 58, **58**

adenocarcinoma-in-situ (AIS)
case scenario 189
progression to cancer
risk factors for 192

recurrence of
risk factors for 192

adenomyectomy
in adenomyosis pain management 81

adenomyosis 75–87
background 76

- case scenario 75
- clinical questions 76–83
- diffuse 76
- evaluation for 77–8
- focal 76
- infertility due to 76
- pain symptoms of
 - management of 79–82
- risk factors for 76
- search strategy 76
- symptoms of 76
- adjuvant analgesics
 - for CPP 52, 53
- AEDs *see* antiepileptic drugs (AEDs)
- AF *see* amniotic fluid (AF)
- age
 - gestational
 - large for 451–2
 - maternal *see* maternal age
- Agency for Healthcare Research and Quality (AHRQ) 6
- aging
 - ovarian
 - menopause and 156
- AHRQ *see* Agency for Healthcare Research and Quality (AHRQ)
- AIS *see* adenocarcinoma-in-situ (AIS)
- alcohol use
 - preconception care related to 207–8
- alkaline hematin
 - for vaginal bleeding 66
- amenorrhea 109–16 *see also* specific types
 - background 109
 - case scenario 109
 - causes of 109–13
 - classification of 109
 - clinical questions 109–13
 - defined 109
 - endocrine disorders and 110–11
 - evaluation of 109–10
 - hypothalamic 111
 - menopause and 112–13
 - menstrual physiology in 110
 - mosaicism and 111
 - outflow tract abnormalities resulting in 110
 - PCOS and 112
 - pituitary disorders and 111–12
 - primary *see* primary amenorrhea
 - pure gonadal dysgenesis and 111
 - secondary *see* secondary amenorrhea
 - treatment of 113
- American College of Obstetricians and Gynecologists (ACOG)
 - on aneuploidy screening 213
 - on diagnostic tests for RPL 132
 - on HG management 229
 - on second stage of labor 569
 - on VTE prevention during pregnancy 359
- American Society of Reproductive Medicine (ASRM)
 - endometriosis staging system of 75
- amitriptyline
 - for CPP 52, 53
- amniocentesis
 - in NTDs detection 220
 - for pregnant women at high risk for aneuploidy 218–19
- amnioreduction (AR)
 - in polyhydramnios management 445–6
- amniotic fluid (AF)
 - excessive *see* polyhydramnios
- amniotic fluid (AF) abnormalities
 - perinatal outcome related to
 - ultrasound in detection of 444, 444
- amniotic fluid (AF) volume
 - background 443
 - described 443
 - disorders of 443–9 *see also* polyhydramnios
 - case scenario 443, 447
 - clinical questions 443–7
- amniotomy
 - in cervical ripening 531, 532
- AmniSure ROM Test 398
- AMORIPAT *see* active management of risk in pregnancy at term (AMORIPAT)
- AMTSL *see* active management of third stage of labor (AMTSL)
- AN *see* acanthosis nigra (AN)
- analgesics
 - for CPP 52, 53
- anemia
 - acute
 - HMB and 15
 - blood loss
 - management of 336, 336
- anesthesia/anesthetics
 - for cesarean delivery in obese women 595–6
 - conduction
 - labor courses related to 537
- aneuploidy
 - pregnant women at risk for
 - cfDNA analysis for 213–14
 - prenatal diagnosis for 213–23 *see also* prenatal diagnosis
 - screening for 213
- angiotensin-converting enzyme (ACE) inhibitors
 - fetal effects of 238, 239, 238
- antenatal corticosteroids 2
 - in reducing morbidity and mortality from preterm birth 388, 390, 391
- antepartum factors
 - impact on uterine rupture 420
- antepartum hemorrhage (APH) 407–17
 - background 407
 - case scenario 407, 411, 413
 - causes of 407
 - clinical questions 407–11
 - defined 407
 - management of 407
 - prevalence of 407
 - undetermined/unexplained
 - expectant management for 413
- antepartum/intrapartum fetal surveillance 495–511
 - introduction 495
- anti-androgens

- in PCOS management 124
- antianxiolytics
 - during pregnancy 206
- antibiotic prophylaxis
 - for cesarean delivery in obese women 594–5
- antibiotics
 - prophylactic *see* prophylactic antibiotics
- antibody screen
 - in women with EP 42
- anticoagulant therapy
 - for RPL 138–40, 139
- antidepressant(s)
 - breastfeeding while taking 380
 - discontinuing
 - among women who wish to or have recently conceived 377–8
 - during pregnancy 207
- antiemetics
 - in pregnancy 228, 229
- antiepileptic drugs (AEDs)
 - during pregnancy
 - concerns related to 316–17
 - pharmacokinetic changes related to 316
- antifibrinolytics
 - for HMB 15–16
- antihypertensive agents
 - in preconception care 204–5
- antioxidants
 - in FGR management and prevention 457
- antiphospholipid antibodies
 - pre-eclampsia and 257
- antiphospholipid syndrome (APS) 135–7, 138
 - β-hCG for 325–33
 - case scenarios 131, 325–6
 - catastrophic *see* catastrophic antiphospholipid syndrome (CAPS)
 - classification criteria for 327–8, 327
 - clinical presentation of 326–7
 - clinical questions 326–30
 - definite 327–8, 327
 - diagnosis of 326
 - introduction 325
 - obstetric
 - case scenario 325
 - possible or probable 325–6, 328
 - during pregnancy
 - complications related to 326–7
 - considerations related to 330–1
 - management of 136–41, 138, 139, 140, 328–9
 - “refractory obstetric”
 - management of 329–30
 - as risk factor for RPL 133–4
 - thrombotic
 - case scenario 325
- antipsychotics
 - during lactation 380–1
 - during pregnancy 206
- antithrombin deficiency (ATD)
 - during pregnancy 356, 356, 357
- aortic disease
 - congenital
 - in pregnancy 276
 - aortopathies
 - in pregnancy 275
- APH *see* antepartum hemorrhage (APH)
- appendicitis
 - possible
 - exploratory surgery for 372
 - in pregnancy 372
 - in pregnancy 369–73
 - background 369–70
 - clinical questions 370–3, 370, 371
 - delay in treatment of 372–3
 - diagnosis of 370–2, 370, 371
 - maternal and fetal risks associated with 372–3
- APS *see* antiphospholipid syndrome (APS)
- AR *see* amnioreduction (AR)
- Arias–Stella reaction 36
- aromatase inhibitors
 - in endometriosis pain management 78–9
 - for unexplained subfertility 147–8
- arrest of labor
 - defined 535
- arterial ligation
 - in PPH management 549
- artificial valves
 - during pregnancy 270–1
- ARTs *see* assisted reproductive technologies (ARTs)
- ASDs *see* atrioventricular septal defects (ASDs)
- Asherman syndrome 550
- aspiration
 - vacuum
 - induced abortion by 23, 24
- aspirin
 - for hereditary thrombophilias 139
- low-dose
 - in FGR management and prevention 457
 - in reducing risk of pre-eclampsia 257
 - for patients with RPL and APS 136, 139
- ASRM *see* American Society of Reproductive Medicine (ASRM)
 - assisted reproductive technologies (ARTs)
 - EP related to 33, 35
 - heterotopic pregnancy and 33
 - twins after 467
 - zygotic splitting after 467
 - asthma 247–53
 - background 247
 - case scenario 247
 - clinical questions 247–51
 - general search strategy 247
 - pregnant women with
 - agents impacting outcomes of 249–51, 250
 - congenital anomalies 248, 248
 - fetal outcomes related to 247–8, 248
 - management of 249–51, 250
 - outcomes related to 248–51, 250
 - risk factors related to 247–8, 248

antiphospholipid syndrome (APS) (*continued*)
 stillbirth related to 248, **248**

Atad double-balloon device
 in cervical ripening 532

ATD *see* antithrombin deficiency (ATD)

atrioventricular septal defects (ASDs)
 in pregnancy 273, 274

AUB *see* abnormal uterine bleeding (AUB)

augmentation of labor 527–37
 background 534–5
 case scenario 534
 clinical questions 535–7
 impact on uterine rupture 422, 423–6

auscultation
 intermittent FHR
 vs. randomized trials of EFM 495

autopsy
 for stillbirth 481–2

balloon catheters
 transcervical
 in cervical ripening **531**, 532

balloon tamponade
 in PPH management 549

barrier methods
 in contraception 94

baseline
 defined 497, **498**, **499**

baseline FHR
 defined 497, **498**, **499**
 physiology of 502

bazedoxifene (BZA)
 in menopause 158–9

bed rest
 in preterm labor management 392

benzodiazepine(s)
 during lactation 381
 during pregnancy 206–7

beta-agonists
 inhaled
 impact on pregnancy women with asthma **250**, 251

β -hCG
 measurements of
 in EP 33

beta subunit of human chorionic gonadotropin (β -hCG) *see* β -hCG

bimanual uterine compression
 in PPH management 548–9

biophysical profiles (BPPs)
 in antepartum surveillance of growth-restricted fetuses
 perinatal outcomes of 453

bipolar I disorder
 risk factors for 378
 symptoms of 378

birth(s)
 cesarean *see also* cesarean delivery
 preterm 40
 TOL after previous 419
 multiple 467–77 *see also* multiple pregnancies and births
 premature

defined 397

preterm *see* preterm birth

vaginal *see* vaginal birth

birth control
 methods of 89

birthweight
 low *see* low-birthweight (LBW) infants
 very low *see* very low-birthweight (VLBW) infants

birthweight discordance
 defined 472
 in multiples 472

Bishop score
 modified **530**, **530**

bleeding *see also* hemorrhage
 menstrual *see* menstrual bleeding
 postpartum 545–57 *see also* postpartum hemorrhage (PPH)
 vaginal *see* vaginal bleeding
 in von Willebrand disease
 management of 338–9, **338**

blood loss anemia
 management of **336**, **336**

blue cohosh
 in post-term pregnancy management 436

B-Lynch uterine compression suture
 in PPH management 549, 550

BMI *see* body mass index (BMI)

body mass index (BMI)
 cesarean delivery by women with high 593
 impact on emergency contraception 94
 impact on uterine rupture 420–1
 in pregnant women 569, **571**

bone loss
 menopause and 158

BPPs *see* biophysical profiles (BPPs)

breastfeeding
 antidepressant use while 380
 psychiatric illness in women who are
 medication concentration in breast milk 380–1

breast milk
 medication concentration in 380–1

breech presentation
 delivery with 521
 in later third trimester
 risk factors for 521

breech vaginal delivery
 cesarean delivery *vs.*
 for third trimester malpresentation 521–2

bulimia nervosa
 HG related to 225

“bundle”
 defined 563

BZA *see* bazedoxifene (BZA)

cancer(s) *see also* specific types
 AIS progression to
 risk factors for 192

cervical 165–72
 cervical dysplasia progression to
 risk factors for 192

- CIN progression to
 - risk factors for 192
- endometrial 181–8
- vaginal 173–80
- vulvar 173–80
 - vulvovaginal 174–5, **174**
- cannabis use
 - during pregnancy 207–8
- CAPS *see* catastrophic antiphospholipid syndrome (CAPS)
- carbamazole
 - for Graves' disease in pregnancy 309, **310**
- cardiac disease
 - acquired 267–73 *see also* acquired cardiac disease
 - cyanotic
 - obstetric and fetal risks in women with 275
 - epidemiology of 265–6
 - preconception care in management and prevention of 205
 - preconception counseling for women with 268
 - pregnant women with
 - antibiotic prophylaxis for 272
 - risk assessment models for 266–7, **266**
 - WHO classification system on 267
- cardiomyopathy
 - dilated 279
 - hypertrophic 278
 - peripartum 277–80 *see also* peripartum cardiomyopathy (PPCM)
 - in pregnancy 277–80
 - case scenario 277
 - delivery and monitoring methods for 280
 - postpartum care for 280
 - risk factors for 279
 - restrictive 278–9
 - traditional forms of
 - management of 279–80
 - vs. PPCM 278–9
 - types of 278–9
- cardiopulmonary arrest 565–6
 - case scenario 565
 - in pregnant women
 - immediate *vs.* delayed perimortem/resuscitative cesarean section for 565–6
- cardiovascular disease (CVD) 265–86 *see also* specific diseases, *e.g.*,
 - congenital heart disease
 - acquired cardiac disease 267–73
 - cardiomyopathy 277–80
 - congenital heart disease 273–7
 - contraceptive use and 92
 - introduction 265–7
 - long-term maternal risk of
 - postpartum counseling related to 261–2
 - menopause and 158
 - PPCM 277–80
 - "care bundle"
 - defined 563
 - in management of VTE events in pregnant women admitted to hospital 562–5
- CARPREG risk prediction score
 - for cardiac event during pregnancy 266, **266**
- catastrophic antiphospholipid syndrome (CAPS)
 - classification criteria for 328, **328**
 - described 327
 - during pregnancy
 - management of 330
 - CCT *see* controlled cord traction (CCT)
- CDC *see* Centers for Disease Control and Prevention (CDC)
- CD4 counts
 - low
 - vulvovaginal cancers related to 174
- cell-free fetal DNA (cfDNA) analysis
 - for pregnant women at risk for aneuploidy 213–14
 - in Trisomy 21 and Trisomy 18 detection 213–14
- Centers for Disease Control and Prevention (CDC)
 - Preconception Health and Health Care Initiative of 201, 202
 - USMEC of 92
- central nervous system (CNS)
 - in CPP 50–1
- cephalic presentation
 - ECV in effort to turn fetus into 521
- cervical cancer 165–72
 - background 165, 165
 - case scenario 165
 - causes of 165
 - clinical presentation of 165
 - clinical questions 166–9
 - early-stage
 - treatment of 168–9, **169**
 - HPV and 165, 167
 - incidence of 165
 - prevalence of 165
 - risk factors for 166–7, **166**
 - squamous cell carcinoma 165
 - staging of 168–9, **169**
 - symptoms of 165
 - treatment of
 - stage-related 168–9, **169**
 - types of 167
- cervical cerclage
 - PPROM management related to 402
- cervical dysplasia 189–95 *see also* cervical intraepithelial neoplasia (CIN)
 - background 189
 - case scenario 189
 - causes of 189
 - clinical questions 189–93
 - defined 189
 - general search strategy 189–90
 - management of
 - in pregnant patients 193
 - risks of preterm delivery after 192–3
 - prevention of
 - HPV vaccines in 191–2
 - progression to cancer
 - risk factors for 192
 - recurrence of
 - risk factors for 192
 - risk factors for 191
- cervical ectopic pregnancy (EP)

cervical ectopic pregnancy (EP) (*continued*)
 local therapy in 42

cervical injury
 induced abortion and 25–6

cervical intraepithelial neoplasia (CIN) 189–95 *see also* cervical dysplasia
 AIS-related
 prevalence of 190–1
 categories of 190
 clinical questions 189–93
 defined 189
 detection of
 diagnostic tests *vs.* cervical cytology in 167–8
 HPV and 165, 167, 189–95 *see also* human papillomavirus (HPV)
 prevention of
 HPV vaccines in 191–2

progression to cancer
 risk factors for 192

recurrence of
 risk factors for 192

risk factors for 191

treatment of
 ablative procedures in 190
 CKC in 191
 costs related to 190
 cryotherapy in 191
 excisional procedures in 191
 laser ablation in 191
 laser conization in 191
 LEEP in 191
 LLETZ in 191
 risks of preterm delivery after 192–3

cervical ripening
 described 531
 methods of 531–3, **531**

cesarean birth
 preterm
 uterine rupture related to 420
 TOL after previous 419

cesarean delivery
 BMI risks related to 593
 breech vaginal delivery *vs.*
 for third trimester malpresentation 521–2
 complications following 593
 induction of labor and 528–9
 oxytocin related to 533–4
 maternal–fetal complications of 585, **586**
 in obese women 593–9
 anesthesia considerations 595–6
 antibiotic prophylaxis for 594–5
 case scenario 593
 clinical questions 593–7
 LMWH for 596–7
 technical surgical aspects at 594
 thromboprophylaxis for 596–7
 for pregnant women with cardiopulmonary arrest 565–6
 prevalence of 583

prophylactic induction of labor for fetal macrosomia in
 decreasing risk for 458, 460
 in shoulder dystocia prevention 460, **460**
 technical surgical aspects at 594
 vacuum extraction at
 safety considerations 587
 vaginal birth after 419–30 *see also* vaginal birth after cesarean (VBAC) delivery

cfDNA *see* cell-free fetal DNA (cfDNA) analysis

chlamydia
 clinical presentations of 55–6
 diagnosis of 56–7
 treatment of 57–8

cholecystectomy
 laparoscopic
 for cholelithiasis in pregnancy 366–7

open
 for cholelithiasis in pregnancy 366–7

cholelithiasis
 described 365
 in pregnancy 365–7
 clinical questions 365–7
 described 365
 diagnosis of 365–6
 management of 366–7

chorionic villous sampling (CVS)
 for pregnant women at high risk for aneuploidy 218

chromosome microarray analysis
 in fetal anomalies diagnostic testing 487–8
 for pregnant women at high risk for aneuploidy 219

chronic diseases
 management of
 medications in 206–7
 preconception care in 203–6

chronic hypertension 258
 preconception care for women with 204–5

chronic kidney disease (CKD)
 classification of 288–9, **288**
 in pregnant women 287–96
 background 288–90, **288–90**
 considerations 288–90, **288–90**
 impact of 289, **289**
 management of 290–4
 perinatal morbidity and mortality associated with 287
 prevalence of 287

chronic pelvic pain (CPP) 49–54
 causes of
 laparoscopy in identifying 51–2
 clinical questions 50–2
 CNS in 50–1
 defined 49
 general search strategy 50
 initial consultation influencing 51
 management of 52, **53**, 53
 consensus on approach to 49–50

musculo-skeletal abnormalities in women of reproductive age
 with 51
 presentation of 49

chronic salpingitis

- EP and 35
- cigarette smoking
 - during pregnancy *see* smoking
- CIL *see* complete inguinalfemoral lymphadenectomy (CIL)
- CIN *see* cervical intraepithelial neoplasia (CIN)
- CIN 1
 - described 190
- CIN 2
 - described 190
 - recurrence risk and progression to cancer in women 192
- CIN 3
 - described 190
 - recurrence risk and progression to cancer in women 192
- CKC *see* cold knife conization (CKC)
- CKD *see* chronic kidney disease (CKD)
- clinical scoring systems
 - types of 561, **564**
- clomiphene citrate
 - for unexplained subfertility 146–7
- CMV *see* cytomegalovirus (CMV)
- CNS *see* central nervous system (CNS)
- Cochrane Collaboration 2, 5, **5**
- COCs *see* combined oral contraceptives (COCs)
- cognition
 - menopause effects on 158
- cognitive decline
 - menopause and 158
- cold knife conization (CKC)
 - in CIN management 191
- Collaborative Perinatal Project 569
- Collaborative Review of Sterilization (CREST) 90
- colpocleisis
 - in uterine prolapse management 102–3
- combined first and second trimester screening
 - for pregnant women with low or average risk for aneuploidy
 - in Trisomy 21 and Trisomy 18 detection 215–16, **215**
- combined oral contraceptives (COCs)
 - in endometriosis pain management 78
 - for HMB 16, **17**
 - in PCOS management 123–4
- complementary and alternative medicine
 - in post-term pregnancy management 435–6
- complete inguinalfemoral lymphadenectomy (CIL)
 - in early-stage vulvar cancer management 175–6
- compression sutures
 - in PPH management 549–50, 550
- computed tomography (CT)
 - in appendicitis in pregnancy 371–2, **371**
- computed tomography pulmonary angiogram (CTPA)
 - for VTE in pregnancy 561, **563**
- conception(s)
 - DZ 467–8
 - MZ 467–8
 - retained products of
 - induced abortion and 26
- condoms
 - in contraception 94
- conduction anesthesia
- labor courses related to 537
- Confidential Enquiries into Maternal Death 595
- congenital anomalies
 - oligohydramnios 488
 - single umbilical artery 488
 - stillbirth related to 490
 - in twins 488
 - in women with asthma 248, **248**
- congenital aortic disease
 - in pregnancy 276
- congenital heart disease 273–7
 - clinical questions 273–7
 - preconception care in management and prevention of 205
 - in pregnant women
 - antenpartum management for 273
 - case scenario 273
 - maternal risks associated with 274–5
 - obstetric, fetal, and neonatal risks associated with 275–6
 - postpartum care for 277
 - preferred labor and delivery methods for 276
 - recurrence risk for subsequent child 273–4
- congenital pulmonary airway malformation (CPAM)
 - clinical questions 514–18
 - defined 513
 - diagnosis of
 - prognosis related to 517–18
 - hydrops fetalis with 513–19
 - case scenario 513–14, 514, 515
 - incidence of 513
 - prognosis of 513
 - treatment of 514, 515
 - in-utero 518
 - types of 518
- conjoined twins 467
- Consortium on Safe Labor (CSL) 569
- contingent screening
 - for pregnant women with low or average risk for aneuploidy
 - in Trisomy 21 and Trisomy 18 detection 216
- contraception 89–97 *see also* contraceptive use
 - background 89
 - barrier methods 94
 - case scenario 89, 94–5
 - clinical questions 89–93
 - effectiveness of
 - determinants of 90–1, **91**
 - emergency 94
 - general search strategy 90
 - LARC methods 89, 92
 - non-LARC methods 92–3
- contraceptive(s)
 - combined oral *see* combined oral contraceptives (COCs)
 - oral
 - in endometriosis pain management 78
 - risk factors associated with 92
- Contraceptive Choice Project 89
- contraceptive methods *see also* specific types
 - after induced abortion 27–8
- contraceptive use *see also* contraception
 - cardiovascular disease and 92
 - medical eligibility criteria for 91–2

contraceptive use *see also* contraception (*continued*)
 smoking and 92
 unintended pregnancy during 91, **91**

controlled cord traction (CCT)
 in third stage of labor 576, 577

"Core Principles and Values of Effective Team-Based Health Care," 559

corticosteroids
 antenatal 2
 in reducing morbidity and mortality from preterm birth 388, 390, 391
 in HG management 230
 inhaled
 impact on pregnant women with asthma 249–51, **250**
 in PPROM management 399–400

Coumadin
 during pregnancy 206

Council on Patient Safety in Women's Healthcare 563

counseling
 fertility desires-related 90
 on long-term health risks associated with PCOS 125–6, **126**
 postpartum
 on long-term maternal risk of CVD 261–2

preconception
 for women with cardiac disease 268
 for women with diabetes 203–4

pregnancy spacing and limiting-related 90

prior to induced abortion 22

sterilization methods-related 90

CPAM *see* congenital pulmonary airway malformation (CPAM)

CPP *see* chronic pelvic pain (CPP)

CREST *see* Collaborative Review of Sterilization (CREST)

cryotherapy
 in CIN management 191

CSL *see* Consortium on Safe Labor (CSL)

CT *see* computed tomography (CT)

CTPA *see* computed tomography pulmonary angiogram (CTPA)

cultoplasty
 McCall
 in pelvic organ prolapse management 103

CVD *see* cardiovascular disease (CVD)

CVS *see* chorionic villous sampling (CVS)

cyanotic heart disease
 obstetric and fetal risks in women with
 oxygen saturation in assessing 275

cystocele repair 104

cystoscopy
 in pelvic organ prolapse repair 105

cytokine modulation
 for unexplained RPL 140

cytomegalovirus (CMV)
 in pregnancy 343–5, **344**, 344, **345**, 345
 level of evidence 350

danazol
 in adenomyosis pain management 79
 in endometriosis pain management 79

DC placenta *see* dichorionic (DC) placenta

D&E *see* dilatation and evacuation (D&E)

deceleration(s)

defined 498, 499–500, **499**, 501, 500
 early 498, 499–500, 500
 in FHR
 physiology of 502–3, 503
 late 498, **499**, 500, 500
 prolonged 498, **499**, 500
 variable 498, **499**, 500, 501

deeply infiltrating endometriosis (DIE)
 laparoscopic management of 80
 prevalence of 76

deep vein thrombosis (DVT)
 case scenario 355
 during pregnancy
 diagnosis of 357

delayed postpartum pre-eclampsia
 defined 256–7

delivery *see also* labor and delivery
 cardiomyopathy in 280
 forceps *vs.* vacuum 583–4, 585
 operative vaginal 583–91 *see also* operative vaginal delivery (OVD)
 spontaneous 569–81 *see also* spontaneous delivery

VBAC 419–30 *see also* vaginal birth after cesarean (VBAC)

delivery

depression
 menopause and 157–8
 postpartum 377
 pregnancy-related 377–84
 case scenario 377
 clinical questions 377–81
 prevalence of 377
 psychiatric disease risk factors associated with 378
 in women who wish to or have recently conceived
 discontinuance of psychiatric medications by 377–8

DES *see* diethylstilboestrol (DES)

diabetes mellitus (DM) 297–302 *see also* gestational diabetes mellitus (GDM)
 case scenario 297
 clinical questions 297–302
 gestational *see* gestational diabetes mellitus (GDM)
 preconception counseling for women with 203–4
 pregestational
 preconception control of 203–4

in pregnancy
 types of 297, **298**
 White classification for 297, **298**

diabetic nephropathy
 in pregnancy 291

dialysis
 for CKD in pregnancy 292–3

dichorionic (DC) placenta 467–8

DIE *see* deeply infiltrating endometriosis (DIE)

diet
 in HG management 228

diethylstilboestrol (DES) 2

diffuse adenomyosis 76

dilatation and evacuation (D&E)
 induced abortion by 24–5
 for mid-trimester induction of labor 538, **538**

dilated cardiomyopathy 279

- dilator(s)
 - hygrosopic
 - in cervical ripening **531, 532**
- dimenhydrinate
 - in HG management **228, 229**
- dizygotic (DZ) conceptions **467–8**
- DM *see* diabetes mellitus (DM)
- Doppler studies
 - in identifying growth-restricted fetuses at risk for adverse pregnancy outcomes **453–6, 454, 455, 456**
- doxylamine
 - in HG management **229**
- droperidol
 - in HG management **230**
- drug(s) *see also* specific types and medication(s)
- drug absorption
 - physiologic changes during pregnancy effects on **234, 235**
- drug disposition
 - physiologic changes during pregnancy effects on **234–6, 235**
- drug distribution
 - physiologic changes during pregnancy effects on **234, 235**
- drug elimination
 - physiologic changes during pregnancy effects on **235, 236**
- drug metabolism
 - physiologic changes during pregnancy effects on **234–6, 235**
- drug toxicities
 - fetal **238, 239**
- drug use
 - recreational
 - preconception care related to **207–8**
 - D-transposition of great arteries
 - in pregnancy **274**
 - L-transposition of great arteries *vs.* **275**
 - duloxetine
 - for CPP **52, 53**
 - duplex compression sonography
 - for VTE in pregnancy **561, 563**
 - DVT *see* deep vein thrombosis (DVT)
 - dysfunctional uterine bleeding **13**
 - dysplasia(s)
 - cervical **189–95** *see also* cervical intraepithelial neoplasia (CIN); CIN
 - dystocia
 - shoulder
 - cesarean delivery in prevention of **460, 460**
 - DZ conceptions *see* dizygotic (DZ) conceptions
 - early deceleration
 - defined **498, 499–500, 500**
 - physiology of **502**
 - early miscarriage
 - recurrent
 - APS and **326**
 - “Early Obstetrical Warning System”
 - in management of VTE events in pregnant women admitted to hospital **562–5**
 - EBM *see* evidence-based medicine (EBM)
 - echocardiography
 - fetal **489**
 - ecclampsia
 - in mothers of multiple gestations **468, 469**
 - ectopic pregnancy (EP)
 - ARTs and **33, 35**
 - background **33**
 - causes of **35–6**
 - cervical
 - local therapy in **42**
 - clinical questions **34–9**
 - defined **33**
 - described **35**
 - diagnosis of **36–8**
 - epidemiology of **34**
 - heterotopic
 - local therapy in **42**
 - historical perspective **34**
 - incidence of **34**
 - interstitial
 - local therapy in **41**
 - management of **39–42**
 - expectant **42**
 - local therapy **41–2**
 - medical **40–1**
 - surgical **39–40**
 - miscarriage *vs.* **39**
 - morbidity and mortality effects of **34**
 - ovarian
 - local therapy in **42**
 - prevalence of **33**
 - PUL **38**
 - Rh status and antibody screen in women with **42**
 - risk factors for **34–5**
 - sites of **35**
 - symptoms of **35–8**
 - ectopic pregnancy (EP) rupture **36**
 - ECV *see* external cephalic version (ECV)
 - EFM *see* electronic fetal heart rate monitoring (EFM)
 - EFW *see* estimated fetal weight (EFW)
 - electronic fetal heart rate monitoring (EFM) *see also under* fetal heart rate (FHR)
 - adjunct methods of **508–9**
 - background **495**
 - criteria for hypoxic neurologic injury **504–5, 505, 505**
 - interpretation of **503–5, 504, 504, 505, 505**
 - interruption of oxygen transfer from environment to fetus during **503–4, 504, 504**
 - management with **505–8, 506, 507**
 - confirm FHR and uterine activity **505, 506**
 - evaluate FHR components **505–6, 507**
 - expectant management *vs.* delivery **508**
 - re-evaluate FHR tracing **506–8, 506, 507**
 - principles of **504, 505**
 - randomized trials of
 - vs.* intermittent FHR auscultation **495**
 - embryonic anomalies
 - EP and **35–6**
 - embryonic demise
 - multiple pregnancies and births and **470**
 - emergency(ies)
 - obstetric **559–68** *see also* specific types and obstetric emergencies

emergency(ies) (*continued*)

- emergency contraception 94
- endocrine disorders
 - amenorrhea 109–13
- endometrial ablation/resection
 - in HMB management 18, **18**
- endometrial cancer 181–8
 - case scenario 181
 - clinical questions 181–6
 - minimally invasive surgery for 183–4
 - premenopausal women with
 - Lynch syndrome in 186
 - ovarian removal in management of 184–5
 - prognosis of 184–5
 - prognosis of
 - lymph node dissection in 181–3
- endometrioma
 - fertility effects of 81–2
- endometriosis 75–87
 - ASRM staging system for 75
 - background 75–6
 - case scenario 75
 - clinical questions 76–83
 - deeply infiltrating 76, 80
 - evaluation for 77
 - hysterectomy for
 - ovarian preservation in women undergoing 83
 - infertility due to
 - management of 82
 - management of
 - peri-operative medical therapy in 82–3
 - manifestations of 75–6
 - pain symptoms of
 - management of 78–80
 - prevalence of 75
 - search strategy 76
 - severity of 75
 - sites of 75
 - types of 75–6
- environmental toxins
 - preconception care related to 207–8
- EP *see* ectopic pregnancy (EP)
- EPCs program *see* US Evidence-based Practice Centers (EPCs) Program
- epilepsy
 - case scenario 315
 - clinical questions 316–17
 - grading of evidence 317
 - in pregnancy 315–17
 - background 315–16
 - fetal effects of 238–9, **239**
 - prevalence of 315
 - search strategy 317
 - seizures in
 - causes of 316
- ergometrine
 - in AMTSL 577
- ESHRE *see* European Society of Human Reproduction and Embryology (ESHRE)
- ESHRE/ESGE classification system
 - of fibroids 63
- Essure sterilization 93
- estimated fetal weight (EFW)
 - case scenario 451
 - cesarean delivery and
 - in shoulder dystocia prevention 460, **460**
 - in multiples 472
- estrogen
 - for menopause 158
- EURAP *see* International Registry of Antiepileptic Drugs and Pregnancy (EURAP)
- European Society of Human Reproduction and Embryology (ESHRE)
 - on diagnostic tests for RPL 132, 133
- evidence-based medicine (EBM)
 - defined 2
 - in OB/GYN 1–7
 - Cochrane Collaboration 5, **5**
 - critically appraising studies and assessing strength of literature 4–5, **5**
 - EPCs Program in 5–6
 - evidence-based resources 5, **5**
 - formulating questions 3–4, **3**
 - history 1–2
 - literature search and identifying relevant studies 4
 - steps in 3, **3**
 - systematic review processes 2–3, **3**, 2
 - USPSTF in 5–6
 - for RPL 140–1
 - evidence-based obstetrics
 - steps in 3, **3**
 - excisional procedures
 - in CIN management 191
 - external cephalic version (ECV)
 - in effort to turn fetus into cephalic presentation 521
 - for third trimester malpresentation 522–3
 - failed abortion 26–7
 - fallopian tubes
 - EP within 35
 - famciclovir
 - for recurrent HSV infection 58, **58**
 - FASTER trial 215–16, 490
 - female pattern hair loss
 - PCOS and 122, 122
 - Ferriman-Gallwey (FG) scoring system 120–2, 120–2, **122**
 - fertility
 - endometrioma impact on 81–2
 - fibroids effect on 65, **65**
 - fertility desires
 - counseling related to 90
 - fetal anomalies 487–94
 - background 487
 - case scenario 487
 - delivery mode and timing related to 489–90
 - diagnosis of
 - associated findings 488
 - chromosome microarray analysis in 487–8

- imaging in 488–9
- genetics of 487–8
- introduction 487
- management of
 - surgical 489
- maternal risks associated with 490–1
- prevalence of 487
- risk factors for 490
- termination due to 490
- twinning and 488
- types of 487
- fetal assessment
 - multiple pregnancies and births and 472–3, 473
- fetal death
 - APS and 326
- fetal demise
 - intrauterine 479–85 *see also* stillbirth(s)
 - mid-trimester induction of labor secondary to
 - induction of labor *vs.* D&E for 538, 538
 - multiple pregnancies and births and 470
- fetal drug toxicities 238, 239
- fetal fibronectin (FFN)
 - in identifying risk factors for preterm birth 387
- fetal growth
 - disorders of 451–65 *see also* specific disorders
 - background 451–2
 - case scenario 451, 460–1
 - clinical questions 452–60
 - multiple pregnancies and births impact on 472
 - fetal growth restriction (FGR) 451–65 *see also* fetal growth, disorders of; growth-restricted fetuses
 - antenatal surveillance of
 - perinatal outcomes of 453
 - case scenario 451, 460–1
 - defined 451
 - detection of
 - customized fetal growth curves in 452–3
 - management of
 - vitamins and antioxidants in 457
 - in multiples 472
 - neonatal health consequences of 458, 459
 - neurodevelopmental outcomes associated with 458, 459
 - prevention of
 - vitamins and antioxidants in 457
 - fetal heart rate (FHR) 499
 - fetal heart rate (FHR) auscultation
 - EFM *vs.* 495, 496
 - fetal heart rate (FHR) definitions
 - acceleration 498, 499, 499
 - baseline 497, 498, 499
 - deceleration 498, 499–500, 499, 501, 500
 - NICHHD on 497–501
 - sinusoidal pattern 498, 499, 500–1, 501
 - standardized
 - evolution of 495, 497
 - variability 497–9, 498, 499, 499
 - fetal heart rate (FHR) patterns
 - physiology of 501–3, 503
 - accelerations 502
 - baseline 502
 - decelerations 502–3, 503
 - variability 502
 - fetal karyotype
 - abnormal 133
 - fetal macrosomia
 - prophylactic induction of labor for 458, 460
 - fetal neuroprotection
 - magnesium sulfate in 400
 - fetal presentations
 - types of 521
 - fetal pulse oximetry
 - in intrapartum FHR monitoring 508
 - fetal thyroid disease 310
 - fetal warfarin syndrome 206
 - fetal well-being
 - in post-term pregnancy
 - tests for 434–5
 - fetus(es) *see also under* fetal
 - appendicitis in pregnancy risks to 372–3
 - breakthrough seizures impact on 316
 - cesarean delivery–related effects on 585, 586
 - congenital heart disease in pregnant women effects on 275–6
 - drug toxicities affecting 238, 239
 - echocardiography of 489
 - GDM effects on 298
 - Graves' disease in pregnancy effects on 308–10
 - growth-restricted *see* growth-restricted fetuses
 - HG effects on 226
 - induction of labor effects on 527–30, 528
 - maternal asthma effects on 247–8, 248
 - maternal pharmacotherapy effects on 238–9, 239, 238
 - MG effects on 321
 - multiple pregnancies and births impact on 469–73, 469, 471, 473
 - OVD–related effects on 585, 586
 - post-term pregnancy risk factors for 432, 433
 - size of
 - impact on uterine rupture 421
 - valvular lesions during pregnancy effects on 271
 - FFN *see* fetal fibronectin (FFN)
 - FGR *see* fetal growth restriction (FGR)
 - FHA *see* functional hypothalamic amenorrhea (FHA)
 - FHR *see* fetal heart rate (FHR)
 - fibroid(s) 63–74
 - causes of 64
 - classification of 63
 - diagnosis of 64, 65
 - epidemiology of 63
 - ESHRE/ESGE classification system of 63
 - evidence-based pregnancy outcomes related to 65–6, 65, 66
 - fertility effects of 65, 65
 - HLRCC and 64
 - introduction 63
 - management of
 - effects of 70
 - evidence-based 65, 67–9
 - LNG-IUDs 68
 - medical 67–8

fibroid(s) (*continued*)
 MRg-FUS in 68–9, **70**
 surgical 67
 pressure/pain from 65
 prevalence of 63
 quantitative measures of 66–7
 uterine 63–74
 vaginal bleeding related to 65

fibronectin
 fetal
 in identifying risk factors for preterm birth 387

FIGO *see* International Federation of Gynecology and Obstetrics (FIGO)

First and Second Trimester Evaluation at Risk (FASTER) trial 215–16, 490

first stage of labor
 clinical questions 570–1, **570, 570**
 Greenberg maternal age median length of **571**

first trimester
 combined screening
 in pregnant women with low or average risk for aneuploidy 214–15, **214**
 induced abortion during
 methods of 23–4
 vaginal bleeding in 33

focal adenomyosis 76

folic acid
 in NTDs prevention 202–3

fondaparinux
 for VTE during pregnancy 359

Fontan procedure 275

forceps delivery
 vacuum delivery *vs.* 583–4, 585

“Friedman’s Curve” 569, 570

functional hypothalamic amenorrhea (FHA) 111

gabapentin
 for CPP 52

gastrointestinal disorders
 in pregnancy 365–76 *see also specific disorders*
 appendicitis 369–73
 cholelithiasis 365–7
 IBD 139
 ICP 368
 pancreatitis 367–8

GDM *see* gestational diabetes mellitus (GDM)

Gemeprost
 in induced abortion 23

general gynecology 11–97

genetics
 of fetal anomalies 487–8

genital herpes simplex virus (HSV)
 clinical presentations of 56
 treatment of 58, **58**

genital tract infections 55–62
 background 55
 case scenario 55
 clinical presentations of 55–6
 during pregnancy 59

clinical questions 55–60
 HSV 56–8, **58**
 search strategy 55
 treatment of 57–60
 in pregnancy 59–60

genital warts
 clinical presentations of 56
 diagnosis of 57
 treatment of 58–9

genitourinary syndrome
 menopause and 157

gestational diabetes mellitus (GDM)
 causes of 297
 diagnostic criteria for 299–300, **299**
 fetal effects of 298
 labor and delivery for women with 300
 maternal blood glucose monitoring and control during 300–1, **300**
 monitoring in postpartum care 301

in mothers of multiple gestations 468, **469**

in pregnancy
 types of 297, **298**
 screening for 297–8
 treatment of 299–300

gestational hypertension 257

gestational transient thyrotoxicosis
 HG related to 226

glomerulonephritis
 acute
vs. pre-eclampsia **292**

glucose intolerance
 classification of 297, **298**

GnRH agonists *see* gonadotropin releasing hormone (GnRH) agonists

gonadotropin(s)
 for unexplained subfertility 147

gonadotropin releasing hormone (GnRH) agonists
 in adenomyosis pain management 79
 in endometriosis pain management 78
 for fibroids 67, **70**

gonorrhea
 clinical presentations of 55
 diagnosis of 56–7
 treatment of 57

GRADE Working Group 4, **4**

Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group 4, **4**

Graves’ disease
 hyperthyroid disease due to
 prevalence of 308

hypothyroid disease due to 303
 in pregnancy 308–10
 fetal risks associated with 308–10
 incidence of 308
 management of 308, 309
 thyroid function and antibody tests for 309–10

GRIT *see* Growth Restriction Intervention Trial (GRIT)

growth-restricted fetuses
 NSTs and BPPs in antepartum surveillance of

- perinatal outcomes of 453
- at risk for adverse pregnancy outcomes
 - Doppler studies in identifying 453–6, 454, 455, **456**
 - timing of delivery for 456–7
- Growth Restriction Intervention Trial (GRIT) 456–7
- gynecology 9–195
 - general 11–97
- hair loss
 - female pattern
 - PCOS and 122, **122**
- Hashimoto's thyroiditis 303
- Hayman suture
 - in PPH management 549, 550
- HCM *see* hypertrophic cardiomyopathy (HCM)
- healthcare teams
 - in obstetric emergencies 566
- heart disease *see specific types and cardiac disease*
- heart valves
 - during pregnancy 270–1
- heavy menstrual bleeding (HMB) 13–20
 - acute anemia with 15
 - background 13–14, **13**
 - clinical questions 14–18
 - management of
 - antifibrinolitics in 15–16
 - COCs in 16, **17**
 - endometrial ablation/resection in 18, **18**
 - hysterectomy in 18, **18**
 - injected/depot progestogens in 18
 - LNG-IUS in 16–18, **17**
 - NSAIDs in 16, **17**
 - oral progestogens in 15, **17**
 - pharmacological 15–18, **17**
 - tests for 14–15
- Helicobacter pylori*
 - HG related to 225–6
- Hellin–Zellany rule
 - for twins, triplets, and quadruplets 467
- HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome 256
- hematologic disease 335–42 *see also specific types*
 - background 335
 - case scenario 335
 - clinical questions 335–40
- hemoglobin disorders
 - during pregnancy
 - identification and management of 336–7, **337**
- hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome 256
- hemorrhage *see also* bleeding
 - antepartum 407–17 *see also* antepartum hemorrhage (APH)
 - induced abortion and 26
 - postpartum 545–57 *see also* postpartum hemorrhage (PPH)
- heparin(s)
 - for hereditary thrombophilias 139, **140**
 - low-molecular weight *see* low-molecular weight heparin (LMWH)
 - during pregnancy 206
- for unexplained RPL 139, **139**
- unfractionated
 - for VTE during pregnancy 358–9
- herbal preparations
 - in HG management 228
 - in post-term pregnancy management 436
- hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
 - fibroids due to 64
- hereditary thrombophilias
 - aspirin for 139
 - heparins for 139, **140**
 - as risk factor for RPL 134
- herpes simplex virus (HSV)
 - diagnosis of 57
 - genital
 - clinical presentations of 56
 - treatment of 58, **58**
 - PPROM management related to 402
- heterotopic ectopic pregnancy (EP)
 - local therapy in 42
- heterotopic pregnancy 33–4
 - ARTs and 33
- HG *see* hyperemesis gravidarum (HG)
- high-order multiple pregnancies
 - hypertensive disorders in 468, **469**
 - rare occurrence of 467
- hirsutism
 - PCOS and 119–22, 120, **122**
- HIV
 - PPROM management related to 402
- HLRCC *see* hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
- HMB *see* heavy menstrual bleeding (HMB)
- hormone replacement therapy (HRT)
 - case scenario 155
 - for menopause 158–9
- hormone supplementation
 - for RPL 137
 - for unexplained RPL 137
- HPV *see* human papillomavirus (HPV)
- HRT *see* hormone replacement therapy (HRT)
- HSV *see* herpes simplex virus (HSV)
- human immunodeficiency virus (HIV)
 - PPROM management related to 402
- human papillomavirus (HPV)
 - cervical cancer related to 165, 167
 - CIN and 165, 167, 189–95
 - prevalence of 190–1
 - clinical questions 189–92
 - detection of
 - diagnostic tests vs. cervical cytology in 167–8
 - vulvovaginal cancers related to 174–5
 - human papillomavirus (HPV) vaccines
 - in CIN prevention 191–2
 - hydration
 - in preterm labor management 392
 - hydrops fetalis 513–19 *see also* congenital pulmonary airway malformation (CPAM)
 - aggravation of

hydrops fetalis (*continued*)
 case scenario 513, 514
 background 513–14
 case scenario 513–14, 514, 515
 classification of 513
 clinical questions 514–18
 CPAM and 513–19
 defined 513
 findings associated with
 case scenario 513, 514
 non-immune
 case scenario 513, 516
 causes of 515, 516
 diagnosis of 515, 517, 517
 incidence of 515
 prevalence of 513
 survival rates 517, 518
 vs. immune 513

hydroxychloroquine
 for SLE 137

hygroscopic dilators
 in cervical ripening 531, 532

hyperandrogenemia 118

hyperandrogenism 118

hyperemesis gravidarum (HG) 225–32
 case scenario 225
 causes of 225–6
 defined 225
 described 225
 differential diagnosis 226–7, 227, 228
 effects of 226
 hyperthyroidism and 310–11
 incidence of 225
 laboratory abnormalities in 227
 laboratory evaluation for 227
 management of 227–30, 228
 ACOG on 229
 acupuncture in 228
 diet in 228
 herbal options in 228
 hypnosis in 228
 non-pharmacologic 228
 pharmacologic 228, 229–30
 recommendations 230
 risk factors for 225
 hypergonadotropic primary amenorrhea 110–11
 hypergonadotropic secondary amenorrhea 111
 hyperprolactinemia
 treatment of 113

hypertension
 chronic 258
 preconception care for women with 204–5
 gestational 257
 pre-existing 258
 superimposed pre-eclampsia on 258–9
 pregnancy-induced 257

hypertensive disorders of pregnancy 255–64
 background 255–9, 256, 259
 case scenario 255, 259–62, 259

categories of 255
 clinical questions 259–62, 259
 in high-order multiple pregnancies 468, 469
 inpatient vs. outpatient evaluation for 259–60
 pre-eclampsia with 257
 risk factors for
 case scenario 259, 259

hyperthyroid disease 308–11
 background 308
 case scenario 308
 causes of 308
 prevalence of 308

hyperthyroidism
 HG and 310–11
 prevalence of 303

hypertrophic cardiomyopathy (HCM) 278

hypnosis
 in HG management 228

hypothalamic amenorrhea 111
 functional 111

hypothalamus
 menopause effects on 156

hypothyroid disease
 defined 303
 poor perinatal and childhood outcomes related to 305–6
 in pregnancy
 clinical questions 304–8
 T4 dose in 304
 thyroid function and antibody tests for 304–5

hypothyroidism
 maternal subclinical 306–7
 poor perinatal and childhood outcomes related to 305–6
 in pregnancy
 routine screening for 307
 subclinical *see* subclinical hypothyroidism
 treatment of 113

hypothyroxinemia
 poor perinatal and childhood outcomes related to 305–6

hypoxic neurologic injury
 criteria for 504–5, 505, 505

hysterectomy
 in adenomyosis pain management 81
 for endometriosis
 ovarian preservation in women undergoing 83
 for fibroids 67, 69
 in HMB management 18, 18

number of
 impact on uterine rupture 421

in placenta accreta management 553
 alternatives to 553–4

in uterine prolapse management 102

hysteropexy
 in uterine prolapse management 102

IBD *see* inflammatory bowel disease (IBD)

ICP *see* intrahepatic cholestasis of pregnancy (ICP)

idiopathic polyhydramnios
 antenatal testing for diagnosis of fetal well-being related to 445

IHI *see* Institute for Healthcare Improvement (IHI)

immunosuppression
 vulvovaginal cancers related to 174–5, **174**

immunotherapy
 for unexplained RPL 139–40

incontinence
 urinary 101–6

indomethacin
 in polyhydramnios management 446–7, **446**

induced abortion 21–32
 background 21
 case scenario 21
 clinical questions 21–8
 contraceptive methods initiated after 27–8
 counseling prior to 22
 failed 26–7
 follow-up after 28
 medical assessments prior to 22
 medical “induction” 24
 methods of
 in first trimester 23–4
 in second trimester 24–5
 prevalence of 21
 risks associated with 25–7
 safety of 21
 subsequent reproduction outcomes related to 27

induction of labor 527–34
 background 527
 benefits of 527
 case scenario 527
 cervical ripening in 531–3, **531** *see also specific methods, e.g.,*
 membrane sweeping
 clinical questions 527–34
 criteria for 527
 described 527
 failed outcome 534
 fetal and maternal outcomes related to 527–30, **528**
 impact on uterine rupture 422, 423–6
 indications for 527–8, **528**
 mid-trimester 537–8, **538** *see also mid-trimester induction of labor*
 oxytocin in 531, 533–4
 cesarean delivery and 533–4
 prevalence of 527
 preventive 528
 prophylactic
 for fetal macrosomia 458, 460
 prostaglandins in 531, 532–3
 risk-based 528
 risk factors for 527–8
 risk of cesarean delivery with 528–9
 success of
 tests in determination of 530–1, **530**
 types of 528

infant(s)
 LBW
 multiple pregnancies and births and 472
 VLBW
 multiple pregnancies and births and 472

infection(s) *see also specific types*

genital tract 55–62 *see also specific types and genital tract infections*
 induced abortion and 26
 in pregnancy 343–54 *see also specific types*
 CMV 343–5
 level of evidence 350
 listeriosis 348–50
 parvovirus 345–6
 VZV 346–8, **347**
 as risk factor for RPL 135

infertility
 adenomyosis and 76
 atypical APS laboratory test results 326
 endometriosis-related
 management of 82
 ovulatory
 PCOS and 124–5, **126**
 PCOS and
 management of 125, **126**
 unexplained 145–53 *see also unexplained subfertility*

inflammatory bowel disease (IBD)
 in pregnancy 139

informed consent
 for OVD 585

inguinofemoral lymph node dissection
 SLND vs.
 in early-stage vulvar cancer detection 175–7, **176**

inhaled beta-agonists
 impact on pregnancy women with asthma 250, 251

inhaled corticosteroids
 impact on pregnant women with asthma 249–51, **250**

injected/depot progestogens
 for HMB 18

Institute for Healthcare Improvement (IHI)
 on “bundle” 563

interdelivery interval
 impact on uterine rupture 421–2

intermittent FHR auscultation
 EFM vs. 495, **496**
 randomized trials of EFM vs. 495

International Federation of Gynecology and Obstetrics (FIGO)
 on AUB 13

International Registry of Antiepileptic Drugs and Pregnancy (EURAP)
 on seizures in pregnancy 315–16

interception care
 aim of 201
 rationale for 202

interception period
 defined 201

interstitial ectopic pregnancy (EP)
 local therapy in 41

interval laparoscopic ligation 93

intrahepatic cholestasis of pregnancy (ICP) 368, 479
 case scenario 482
 causes of 482
 defined 482
 management of
 RCOG on 483

intrahepatic cholestasis of pregnancy (ICP) (*continued*)
 prevalence of 482
 stillbirth and 483
 intrapartum factors
 impact on uterine rupture 422
 intrapartum FHR monitoring
 fetal pulse oximetry in 508
 ST segment analysis in 508
 intrauterine devices (IUDs)
 after induced abortion 27
 levonorgestrel releasing
 for fibroids 68
 progesterone-containing
 for HMB 16–18, **17**
 intrauterine fetal demise 479–85 *see also* stillbirth(s)
 intra-uterine insemination
 for unexplained subfertility 148–9
 intravenous immunoglobulin (IVIg)
 for patients with RPL and APS 136
 in vitro fertilization (IVF) 34
 for unexplained subfertility 149
 iron
 preparations of 336, **336**
 irritable bowel syndrome
 diagnosis of **53**
 ischemic stroke
 during pregnancy 317–19 *see also* stroke, during pregnancy
 isotretinoin
 for acne 207
 during pregnancy 207
 IUDs *see* intrauterine devices (IUDs)
 IVF *see* in vitro fertilization (IVF)
 IVIg *see* intravenous immunoglobulin (IVIg)

karyotype
 abnormal fetal 133

karyotyping
 parental 133

kidney(ies) *see under* chronic kidney disease (CKD); renal
 kidney disease
 chronic *see* chronic kidney disease (CKD)

labor *see also* labor and delivery
 active
 centimeter progression during 570
 initiation of 570
 arrest of 535
 augmentation of 527–37 *see also* augmentation of labor
 course of
 conduction anesthesia impact on 537
 defined 570
 duration of
 maternal age in **571**
 first stage *see* first stage of labor
 functional divisions of 534
 induction of 527–34 *see also* induction of labor
 normal progression of 569
 passive 571
 preterm 385–95 *see also* preterm labor

progression of
 maternal age as factor in 570–1
 obesity effects on 571
 prolonged stage of
 maternal or neonatal morbidity related to 536–7
 prophylactic induction of
 for fetal macrosomia 458, 460
 protracted active phase of
 oxytocin in 535–6
 protracted latent phase of
 management of 535
 pushing during 572, **573**, 572, **575**
 second stage of *see* second stage of labor
 third stage of *see* third stage of labor
 trial of 419

labor and delivery
 GDM and 300
 for growth-restricted fetuses 456–7
 placental abruption and
 timing of 412
 preterm
 in mothers of multiple gestations 469
 spontaneous delivery
 methods for 569–81 *see also* spontaneous delivery
 timing of
 PPROM management and 401
 valvular lesions during pregnancy impact on 271
 for women with congenital cardiac lesions
 preferred methods 276

lactation
 antipsychotic use during 380–1
 benzodiazepine use during 381
 lithium use during 381
 valproate use during 381

laparoscopic cholecystectomy
 for cholelithiasis in pregnancy 366–7

laparoscopic ovarian drilling
 in PCOS management 125

laparoscopic surgery
 in adenomyosis pain management 80
 in EP management 39

laparoscopy
 in adenomyosis pain management 80
 in endometriosis evaluation 77
 for fibroids 69
 in identifying CPP causes in women 51–2
 robotic-assisted
 for fibroids 69
 for unexplained subfertility 149–50

laparotomy
 in endometriosis evaluation 77
 in EP management 39
 for fibroids 69

LARC methods *see* long-acting reversible contraception (LARC)
 methods

large for gestational age (LGA)
 defined 451–2

large loop excision of transformation zone (LLETZ)
 in CIN management 191

laser ablation
 in CIN management 191
 laser conization
 in CIN management 191
 late deceleration
 defined **498, 499**, 500, 500
 physiology of 502–3, 503
 latency period
 PPROM management in 399
 latent labor
 protracted
 management of 535
 LBW *see* low-birthweight (LBW)
 LEEP *see* loop electrosurgical excision procedure (LEEP)
 leiomyomas
 uterine *see* fibroid(s)
 letrozole
 for fibroids 67–8, **70**
 leuprolide
 for fibroids 67
 levonorgestrel releasing intrauterine devices (LNG-IUDs)
 in adenomyosis pain management 79
 for fibroids 68
 LGA *see* large for gestational age (LGA)
 lifestyle modifications
 in PCOS-related infertility management 125, **126**
 listeriosis
 in pregnancy 348–50
 lithium
 during lactation 381
 during pregnancy 206
 LLETZ *see* large loop excision of transformation zone (LLETZ)
 LMWH *see* low-molecular weight heparin (LMWH)
 LNG-IUDs *see* levonorgestrel releasing intrauterine devices (LNG-IUDs)
 LNG-IUS
 for HMB 16–18, **17**
 long-acting reversible contraception (LARC) methods 89
 candidates for 92
 in women with history of STIs 92
 loop electrosurgical excision procedure (LEEP)
 in CIN management 191
 low-birthweight (LBW) infants
 asthma during pregnancy and 248, **248**
 multiple pregnancies and births and 472
 low-dose aspirin
 in FGR management and prevention 457
 low-lying placenta
 diagnosis of 408
 vasa previa related to 414
 low-lying placenta previa
 diagnosis of 408
 low-molecular weight heparin (LMWH)
 in thromboprophylaxis in obese women 596–7
 for VTE during pregnancy 359
 L-transposition of great arteries
 D-transposition of great arteries *vs.* 275
 Lying-in Hospitals 1
 lymph node dissection
 in endometrial cancer prognosis 181–3
 Lynch syndrome
 in premenopausal women with endometrial cancer 186
 macrosomia 452
 fetal
 prophylactic induction of labor for 458, 460
 maternal adverse events associated with 452
 magnesium sulfate
 in PPROM management 400
 in reducing neonatal morbidity and mortality from preterm birth 390–1
 magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
 for fibroids 68–9, **70**
 magnetic resonance imaging (MRI)
 for appendicitis in pregnancy 371–2, **371**
 in fetal anomalies diagnostic testing 488–9
 in low-lying placenta diagnosis 408
 T1- and T2-weighted
 in endometriosis evaluation 77
 major depressive disorder (MDD)
 risk factors for 378
 symptoms of 378
 major depressive episode
 in pregnant women
 adverse perinatal outcomes effects of 378–9
 non-pharmacological treatments for 379–80
 malformation(s)
 fetal–neonatal
 multiple pregnancies and births and 469–70
 malformation syndromes
 stillbirth related to 490
 malpresentation 521–4
 background 521
 defined 521
 ECV in 521
 late third trimester
 risk factors for breech presentation related to 521
 third trimester
 breech vaginal delivery *vs.* cesarean delivery for 521–2
 ECV for 522–3
 Marfan syndrome 273, 275, 276
 massage
 uterine
 in third stage of labor **576, 577**
 maternal age
 in labor duration **571**
 in labor progress 570–1
 in length of second stage of labor 576
 in multiple pregnancies and births 468
 in uterine rupture 420–1
 maternal complications 245–439 *see also* specific types, *e.g.*, asthma
 AF volume disorders 443–9
 antepartum/intrapartum fetal surveillance 495–511
 APH 407–17
 APS 325–33
 asthma 247–53
 CVD 265–86

maternal complications (*continued*)

- depression 377–84
- DM 297–302
- fetal anomalies 487–94
- fetal growth disorders 451–65
- FHR monitoring 495–511
- gastrointestinal disorders 365–76
- GDM 297–302
- hematologic disease 335–42
- hydrops fetalis 513–19
- hypertensive disorders of pregnancy 255–64
- infections 343–54
- intrauterine fetal demise 479–85
- malpresentation 521–4
- multiple pregnancies and births 467–77
- neurologic disease 315–24
- post-term pregnancy 431–9
- PPROM 397–406
- psychiatric disease 377–84
- renal disease 287–96
- stillbirths 479–85
- thyroid disease 303–14
- VBAC delivery 419–30
- VTE 355–63

Maternal-Fetal Medicine Unit Cesarean Registry 593

maternal position

- in second stage of labor 572–3, **573**

maternal serum alpha-fetoprotein (MSAFP) screening

- in NTDs detection 219

maternal subclinical hypothyroidism *see* subclinical hypothyroidism

McCall culdoplasty

- in pelvic organ prolapse management 103

MCDA placenta *see* monochorionic–diamniotic (MCDA) placenta

MCMA placenta *see* monochorionic–monoamniotic (MCMA) placenta

MDD *see* major depressive disorder (MDD)

medical "induction" abortion 24

Medical Outcomes Study Short-Form 36 (SF-36) Health Survey 67

medicated IUDs that release levonogestrel (LNG-IUS)

- for HMB 16–18, **17**

medication(s)

- with known teratogenic potential 206–7, **206**

in pregnancy 233–43

- for asthma 249, **250**
- background 233
- case scenario 233
- clinical questions 233–9
- fetal drug toxicities 238, **239**
- fetal risks associated with 238–9, **239, 238**
- pharmacokinetic changes related to 234–6, **235**
- placenta effects on 236–8, 237

medrol

- dosing schedule for **228**

membrane sweeping

- in cervical ripening 531–2, **531**

memory

- menopause effects on 158

menopause 155–61

- amenorrhea related to 112–13
- bodily effects of 158
- case scenario 155
- clinical questions 156–9
- cognitive effects of 158
- defined 155
- depression in 157–8
- endocrinological changes associated with 156
- genitourinary syndrome and 157
- hypothalamic changes with 156
- memory effects of 158
- mood disorders in 157–8
- ovarian aging with 156
- overview 155
- search strategy 155–6
- sleep disturbances in 157
- symptoms of 157
- treatment of 158–9
- hormonal 158–9
- HRT in 158–9
- indications for 158
- non-hormonal 159
- uterine bleeding and 157
- vasomotor symptoms in 157

menorrhagia 13

menstrual bleeding

- abnormal 13–20 *see also* abnormal menstrual bleeding
- heavy 13–20 *see also* heavy menstrual bleeding (HMB)
- normal 13, **13**

menstrual physiology

- in amenorrhea evaluation 110

metformin

- in PCOS management 125

methimazole

- for Graves' disease in pregnancy 309, **310**

methotrexate (MTX)

- contraindications to 40
- criteria for use 40
- in EP management 40–2

metoclopramide

- in HG management 229

MG *see* myasthenia gravis (MG)

microangiopathic disorders

- during pregnancy 340, **340**

mid-trimester induction of labor 537–8, **538**

- background 537
- case scenario 537
- clinical questions 538
- secondary to lethal anomaly or fetal demise
- induction of labor *vs.* D&E for 538, **538**
- termination methods 538, **538**

mifepristone

- for fibroids 68, **70**
- in induced abortion 23–4

miscarriage 33–47 *see also* recurrent pregnancy loss (RPL)

- atypical APS laboratory test results 326
- background 33
- case scenario 33

- causes of 133
- defined 131
- EP *vs.* 39
- incidence of 33
- prevalence of 131
- recurrent early
 - APS and 326
- misoprostol
 - in AMTSL 577, **577**
 - in induced abortion 23–4
 - in PPH management 546–7, **547**
- monochorionic–diamniotic (MCDA) placenta 467
- monochorionic–monoamniotic (MCMA) placenta 467
- monozygotic (MZ) conceptions 467–8
- mood disorders
 - menopause and 157–8
- morbid obesity
 - case scenario 593
 - cesarean delivery in women with 593
- mosaicism
 - amenorrhea related to 111
- mother(s)
 - age of *see* maternal age
 - appendicitis in pregnancy risks to 372–3
 - cesarean delivery–related effects on 585, **586**
 - fetal anomalies impact on 490–1
 - HG effects on 226
 - induction of labor effects on 527–30, **528**
 - length of second stage of labor impact on 574–5
 - multiple pregnancies and births impact on 468–9, **469**
 - OVD–related effects on 585, **586**
 - post-term pregnancy risk factors for 432, **433**
 - prolonged stage of labor effects on 536–7
- MRg-FUS *see* magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
- MR-HIFU *see* magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
- MS *see* multiple sclerosis (MS)
- MSAFP screening *see* maternal serum alpha-fetoprotein (MSAFP) screening
- MTX *see* methotrexate (MTX)
- multiple pregnancies and births 467–77
 - age as factor in 468
 - birthweight discordance in 472
 - delivery considerations 473–4
 - mode of delivery 474
 - timing of delivery 473–4
 - eclampsia and 468, **469**
 - EFW in 472
 - fetal assessment in 472–3, 473
 - fetal–neonatal consequences of 469–73, **469**, 471, 473
 - embryonic and fetal demise 470
 - fetal growth 472
 - malformations 469–70
 - TTTS 470–2, 471
 - GDM and 468, **469**
 - growth restriction in 472
 - hypertensive disorders and 468, **469**
 - maternal consequences of 468–9, **469**
 - outcome 474–5
 - pre-eclampsia and 468, **469**
 - preterm labor and delivery and 469
 - prevention *vs.* cure 475
- multiple sclerosis (MS)
 - causes of 319
 - during pregnancy 319–20
 - background 319
 - case scenario 319
 - clinical questions 319–20
 - grading of evidence 320
 - management of 320
 - search strategy 320
 - prevalence of 315, 319
 - multiple sexual partners
 - EP related to 35
 - multivitamins
 - in HG management 229
 - musculo-skeletal abnormalities
 - in women of reproductive age with CPP 51
 - myasthenia gravis (MG)
 - during pregnancy 320–2
 - background 321
 - case scenario 320–1
 - clinical questions 321
 - delivery and fetal well-being related to 321
 - grading of evidence 322
 - search strategy 321–2
 - thymectomy in preventing complications 321
 - myomectomy
 - for fibroids 67, **70**
 - MZ conceptions *see* monozygotic (MZ) conceptions
 - NAAT *see* nucleic acid amplification testing (NAAT)
 - National Institute of Child Health and Human Development (NICHD)
 - on FHR definitions 497–501 *see also* specific terms and NICHD definitions
 - National Institute of Child Health and Human Development (NICHD) consensus report (2008) 497, **499**
 - National Partnership for Maternal Safety (NPMS)
 - on VTE prevention during pregnancy 360, **361**
 - natural killer (NK) cells
 - as risk factor for RPL 135
 - neonate(s)
 - congenital heart disease in pregnant women risks to 275–6
 - health consequences of FGR on 458, **459**
 - length of second stage of labor impact on 575–6
 - morbidity and mortality related to
 - preterm labor– and birth–related 388, 390
 - multiple pregnancies and births impact on 469–73, **469**, 471, 473
 - prolonged stage of labor effects on 536–7
 - valvular lesions during pregnancy effects on 271
 - neural tube defects (NTDs)
 - case scenario 201
 - in pregnant women
 - amniocentesis in detection of 220
 - MSAFP in detection of 219

neural tube defects (NTDs) (*continued*)
 ultrasound in 219–20
 prevention of
 folic acid in 202–3

neurologic disease 315–24 *see also specific types*
 epilepsy 315–17
 introduction 315
 MG 320–2
 MS 319–20
 in pregnancy 315–24
 prevalence of 315
 stroke 317–19

neuroprotection
 fetal
 magnesium sulfate in 400

NICHD *see* National Institute of Child Health and Human Development (NICHD)

NICHD definitions
 FHR-related 497–501 *see also specific terms and fetal heart rate (FHR) definitions*
 general considerations 497

NK cells *see* natural killer (NK) cells

nodule(s)
 thyroid
 in pregnancy 311

nonsteroidal anti-inflammatory drugs (NSAIDs)
 for HMB 16, 17

non-stress tests (NSTs)
 in antepartum surveillance of growth-restricted fetuses
 perinatal outcomes of 453

no-scalpel vasectomy (NSV) 93–4

NPMS *see* National Partnership for Maternal Safety (NPMS)

NSAIDs *see* nonsteroidal anti-inflammatory drugs (NSAIDs)

NSTs *see* non-stress tests (NSTs)

NSV *see* no-scalpel vasectomy (NSV)

NTDs *see* neural tube defects (NTDs)

nucleic acid amplification testing (NAAT)
 in genital tract infections 56–7

obese women
 cesarean delivery in 593–9 *see also* cesarean delivery, in obese women
 postpartum thromboembolism in 596–7

obesity
 classification of 593
 defined 205
 impact on length of second stage of labor 576
 labor progression impacted by 571
 morbid 593
 preconception care in management and prevention of 205–6
 prevalence of 593

OB/GYN *see* obstetrics/gynecology (OB/GYN)

obstetric emergencies 559–68
 background 559
 cardiopulmonary arrest 565–6
 healthcare teams performance during 566
 introduction 559
 PE 559–65
 team-oriented care for 559–68

VTE 560

obstetrics/gynecology (OB/GYN)
 EBM in 1–7 *see also* evidence-based medicine (EBM), in OB/GYN

OHSS *see* ovarian hyperstimulation syndrome (OHSS)

oligohydramnios 488

ondansetron
 in HG management 228, 229–30

oocyte anomalies
 EP and 35–6

open cholecystectomy
 for cholelithiasis in pregnancy 366–7

operative delivery
 vaginal delivery *vs.*
 factors in second stage of labor determining 573–4, 573, 575

operative vaginal delivery (OVD) 583–91
 case scenario 583
 clinical options 583
 decreasing trend in 583, 584, 585
 evidence-based procedural aspects of 586
 failed 587–8
 forceps *vs.* vacuum 583–4, 585
 future directions in 589
 guideline considerations for 586
 informed consent for 585
 introduction 583–5, 584, 585
 limitation of pulls and pop-offs in 587–8
 maternal–fetal complications of 585, 586
 pre-procedure checklist and clinical documentation for 585, 587, 588
 prevalence of 583–5, 584, 585
 quality metrics in 590
 safety considerations 587–9
 sequential instruments in 588–9
 training, competency, and simulation in 589
 ultrasound-assisted 589–90

OPK *see* over-the-counter ovulation predictor kit (OPK)

OPTIMAL trial 103

OPTIMUM trial 388

outflow tract abnormalities
 amenorrhea related to 110

ovarian aging
 menopause and 156

ovarian ectopic pregnancy (EP)
 local therapy in 42

ovarian hyperstimulation syndrome (OHSS) 147

ovarian preservation
 in women undergoing hysterectomy for endometriosis 83

ovarian removal
 in endometrial cancer management in premenopausal women 184–5

ovarian stimulation
 for unexplained subfertility 146–8

OVD *see* operative vaginal delivery (OVD)

over-the-counter ovulation predictor kit (OPK)
 in PCOS management 125

overweight
 defined 205
 preconception care in management and prevention of 205–6

- ovulatory infertility
 - PCOS and 124–5, **126**
- Oxford Center for Evidence-based Medicine 4
- oxygen saturation
 - in assessing obstetric and fetal risks in women with cyanotic heart disease 275
- oxygen therapy
 - in FGR management and prevention 457
- oxytocin
 - in AMTSL 576–9, **576**, 578
 - effectiveness of 579
 - optimum dosage of 578, 578
 - optimum timing of 577
 - vs. other medications 577
 - route of 578
 - in cervical ripening **531**, 533–4
 - in induction of labor **531**, 533–4
 - in PPH management **547**, **547**
 - in protracted active phase of labor 535–6
- pain
 - pelvic *see* chronic pelvic pain (CPP); pelvic pain
- pancreatitis
 - in pregnancy 367–8
- paracetamol
 - for CPP 52
- parental karyotyping
 - as risk factor for RPL 133
- parvovirus
 - in pregnancy 345–6
 - level of evidence 350
- passive labor 571
- PBAC *see* pictorial blood loss assessment chart (PBAC)
- PCOS *see* polycystic ovarian syndrome (PCOS)
- PE *see* pulmonary embolism (PE)
- pelvic floor prolapse 101–6 *see also* pelvic organ prolapse
 - background 101
 - case scenario 101
- pelvic organ prolapse 101–6
 - background 101
 - causes of 101
 - described 101–2
 - management of
 - cystoscopy during 105
 - pessaries in 102
 - surgical 102–3
 - types of 102–4
 - prevalence of 101
 - risk factors for 101
 - without SUI
 - management of 104–5
- pelvic pain 49–54
 - background 49–50
 - case scenario 49
 - chronic 49–54 *see also* chronic pelvic pain (CPP)
- PERC *see* Pulmonary Embolism Rule-out Criteria (PERC)
- percutaneous balloon mitral commissurotomy
 - for valvular lesions during pregnancy 270
- perimenopause
 - defined 155
 - endocrinological changes associated with 156
- perinatal mortality
 - asthma during pregnancy and 248, **248**
- peripartum cardiomyopathy (PPCM)
 - case scenario 277
 - clinical questions 277–80
 - defined 277–8
 - diagnosis of 278
 - management of 279–80
 - presenting features of 278
 - risk factors for 277–8
 - traditional forms of cardiomyopathy *vs.* 278–9
- peripartum complications 525–99
 - augmentation of labor 534–7
 - cesarean delivery in obese women 593–9
 - induction of labor 527–34
 - mid-trimester induction of labor 537–8, **538**
 - obstetric emergencies 559–68
 - OVD 583–91
 - PPH 545–57
 - spontaneous delivery 569–81
- pessaries
 - in pelvic organ prolapse management 102
- PGM *see* prothrombin G20210A (PGM)
- PGS *see* pregestational genetic screening (PGS)
- phenothiazines
 - in HG management 229
- PICOTS 3, **3**
- pictorial blood loss assessment chart (PBAC) 66–7
- pituitary disorders
 - amenorrhea related to 111–12
- placenta
 - DC 467–8
 - drug therapy during pregnancy effects of 236–8, 237
 - low-lying
 - diagnosis of 408
 - vasa previa related to 414
 - MCDA 467
 - MCMA 467
 - morbidity adherent
 - methods in controlling/preventing hemorrhage 553–4
 - “rising” 408
 - placenta accreta 551–4
 - case scenario 551
 - clinical questions 552–4
 - incidence of 551
 - management of
 - hysterectomy at time of delivery in 553
 - risk factors for 551
 - placental abruption 411–13
 - case scenario 411
 - clinical questions 411–13
 - delivery timing with 412
 - expectant management for 413
 - prediction of 411
 - prevalence of 412
 - placental arrangement
 - zygosity *vs.* 467

placental arrangement (*continued*)

placental insufficiency

- preterm deliver for
 - APS and 326–7

placenta percreta

- management of 553

placenta previa 407–11

- bleeding
 - tocolysis in management of 409
- case scenario 407
- clinical questions 407–11
- described 407–8
- diagnosis of
 - TVS in 408
- gestational stage for delivery planning and delivery 410
- low-lying
 - diagnosis of 408
- major
 - home management in care of 409–10
- prevalence of 407–8
- “rising placenta” 408
- vaginal birth in pregnancies complicated by 410

placenta previa accreta

- management of 410–11

placenta previa increta

- management of 410–11

placenta previa percreta

- management of 410–11

placentation

- abnormal
 - tests for 552–3

polycystic ovarian syndrome (PCOS) 117–29

- acne and 122, 122
- amenorrhea related to 112
- AN and 122–3, 122
- case scenario 117, 127–8
- causes of 118, 119
- clinical presentation of 119
- clinical questions 117–27
- defined 118, 118
- diagnosis of 119–23, 120–2, 122
- diagnostic criteria for 118, 118, 123
- diagnostic tests for 123, 124, 123
- differential diagnosis 123
- epidemiology of 118–19
- EP related to 34–5
- hirsutism and 119–22, 120, 122
- infertility related to
 - management of 125, 126
- introduction 118
- long-term health risks associated with
 - counseling on 125–6, 126
- management of 123–5
 - anti-androgens in 124
 - COCs in 123–4
 - laparoscopic ovarian drilling in 125
 - lifestyle modifications in 125, 126
 - metformin in 125
 - OPK in 125

- progesterin-only approach in 124
- SERMs in 125
- weight reduction in 125

ovulatory infertility related to 124–5, 126

pregnancy complications related to 125

- prevalence of 118–19
- as risk factor for RPL 134

polyhydramnios

- defined 443
- described 443
- diagnosis of
 - ultrasound in 444, 444
- fetal anomalies detection in pregnant patients with
 - ultrasound in 444–5, 445
- idiopathic
 - antenatal testing for diagnosis of fetal well-being related to 445
- management of
 - AR in 445–6
 - indomethacin in 446–7, 446
- perinatal outcome related to
 - ultrasound in detection of 444, 444

polyzygotic conceptions 467–8

postpartum care

- monitoring of women with GDM 301

postpartum counseling

- on long-term maternal risk of CVD 261–2

postpartum depression

- case scenario 377

postpartum hemorrhage (PPH) 545–57

- background 545, 545
- case scenario 545
- causes of 545, 545
- clinical questions 546–51
- general search strategy 546
- introduction 545
- management of 546–8, 547
 - arterial ligation in 549
 - bimanual uterine compression in 548–9
 - compression sutures in 549–50, 550
 - invasive procedures in 548–51, 550
 - stepwise approach to 546
 - systemic devascularization in 549
 - UAE in 550–1
 - uterine tamponade in 548–9
 - uterotonics in 546–7, 547

placenta accreta and 551–4 *see also* placenta accreta

quantification of 548

- in third stage of labor
 - risk factors for 576
 - uterine atony and 545–51

postpartum period

- self-harm and suicidal ideation in 381

postpartum pre-eclampsia

- delayed
 - defined 256–7

postpartum thromboembolism

- in obese women 596–7

postpartum thyroiditis (PPT) 308

postpartum tubal ligation 93
 post-term pregnancy 431–9
 case scenario 431
 clinical questions 431–6
 defined 431
 evaluation of 434–5
 introduction 431
 management of
 algorithm for 433, **434**
 complementary and alternative medicine approaches in 435–6
 prenatal risks of 432, **433**
 risk factors for 431–2, **433**
 testing during 434–5
 timing for delivery 432–4, **434**
 PPCM *see* peripartum cardiomyopathy (PPCM)
 PPH *see* postpartum hemorrhage (PPH)
 PPROM *see* preterm premature rupture of membranes (PPROM)
 PPT *see* postpartum thyroiditis (PPT)
 preconception care 201–11
 aim of 201
 background 202
 case scenario 201
 in chronic diseases management 203–6
 in chronic hypertension management 204–5
 defined 201
 elements of 201, **208**
 environmental toxins–related 207–8
 introduction 201
 medications/teratogens in 206–7, **206**
 in morbidity and mortality prevention 205
 for overweight and obese women 205–6
 in pregestational diabetes management 203–4
 rationale for 202
 recreational drug use–related 207–8
 substance abuse–related 207–8
 preconception counseling
 for women with cardiac disease 268
 for women with diabetes 203–4
 Preconception Health and Health Care Initiative
 of CDC 201, 202
 prednisolone
 in HG management 230
 during pregnancy 207
 prednisone
 during pregnancy 207
 pre-eclampsia 255–64
 acute glomerulonephritis *vs.* **292**
 antiphospholipid antibodies and 257
 atypical presentation of 256
 clinical presentation of 255, 256
 delayed postpartum
 defined 256–7
 described 255
 diagnosis of
 criteria in 255, **256**
 HELLP syndrome and 256
 hypertensive disorders of pregnancy with 257
 low-dose aspirin in reducing risk of 257
 maternal mortality due to 248, 255–6
 multiple gestations and 468, **469**
 postpartum counseling
 CVD–related issues in 261–2
 preterm delivery for
 APS and 326–7
 prevalence of 255
 risk factors for
 USPSTF on 257
 with severe features
 management of 260–1
 superimposed
 on pre-existing hypertension 258–9
 pre-existing hypertension 258
 superimposed pre-eclampsia on 258–9
 pregabalin
 for CPP 52, **53**
 pregestational diabetes
 preconception control of 203–4
 pregestational genetic screening (PGS)
 in RPL 140
 pregnancy(ies) 274 *see also* pregnant women
 abortion ending
 prevalence of 89
 acquired vascular lesions during
 causes of 268
 AED use during
 concerns related to 316–17
 pharmacokinetic changes related to 316
 antiemetics in **228**, 229
 aortopathies in 275
 APS during
 management of 328–9
 ASDs in 273, 274
 asthma during 247–53 *see also* asthma
 BMI during 569, **571**
 cardiac disease during
 risk assessment models for 266–7, **266**
 cardiomyopathy in 277–80 *see also* cardiomyopathy
 CIN during
 management of 193
 CKD in 287–96, **290** *see also* chronic kidney disease (CKD), in pregnant women
 complications of 131
 PCOS–related 125
 congenital aortic disease in 276
 congenital heart disease in 273–7 *see also* congenital heart disease
 depression during 377–84 *see also* depression
 disorders during *see* psychiatric disease; *specific disorders, e.g., depression*
 DM in 297–302 *see also* diabetes mellitus (DM); gestational diabetes mellitus (GDM)
 D-transposition of great arteries in 274, 275
 ectopic 33–47 *see also* ectopic pregnancy (EP)
 fetal thyroid disease in 310
 fibroids during
 evidence-based outcomes related to 65–6, **65**, **66**

pregnancy(ies) (*continued*)

- gastrointestinal disorders in *see also specific disorders and* gastrointestinal disorders, in pregnancy
- genital tract infections during
 - clinical presentations of 59
 - management of 59–60
- heart valves during 270–1
- hemoglobin disorders during
 - identification and management of 336–7, **337**
- heterotopic 33–4
- HG effects on 226
- hypertensive disorders of 255–64 *see also* hypertensive disorders of pregnancy
- hypothyroid disease in 303–8 *see also* hypothyroid disease
- infections in 343–54 *see also* specific types and infection(s)
- intrahepatic cholestasis of 368, 479, 482–3
- limiting number of
 - counseling related to 90
- major depressive episode during
 - adverse perinatal outcomes effects on 378–9
 - non-pharmacological treatments for 379–80
- maternal mortality during
 - causes of 248
- medications during 206–7, 233–43 *see also* specific types and medication(s), in pregnancy
- MG effects on 320–2
- microangiopathic disorders during 340, **340**
- MS effects on 319–20
- MS medications effects on 320
- multiple 467–77 *see also* multiple pregnancies and births
- neurologic disease in 315–24 *see also* neurologic disease
- normal laboratory parameters in 288, 287
- NTDs in
 - amniocentesis in detection of 220
 - MSAFP in detection of 219
 - second trimester ultrasound in detection of 219–20
- PE during
 - work-up for 560–1, **560–3**
- physiologic changes during 233–4, 265
 - drug disposition effects 234–6, **235**
 - vs. VTE 560, **561**
- placenta previa in 410
- post-term 431–9 *see also* post-term pregnancy
- with prior stillbirth 483–4
 - case scenario 483
- pulmonary valve stenosis in 274–5
- recreational drug use during 207–8
- renal adaptations during 287–8, **288**
- renal disease in
 - types of 291–2
- seizures during 315–16
- smoking during 207
- spacing of
 - counseling related to 90
- stroke in 317–19 *see also* stroke
- target capillary glucose levels in 299, **299**
- term 431
- termination of 21–32 *see also* induced abortion
 - fetal anomalies and 490
- thrombocytopenia during 339, 339–40

- thyroid function effects of 303
- thyroid nodule in
- assessment of 311
- TOF in 274
- TPOAb in 305
- unintended
- causes of 21
- during contraceptive use 91, **91**
- prevalence of 89
- valvular lesions in *see* valvular lesions, during pregnancy
- VSDs in 274
- VTE during 355–63 *see also* venous thromboembolism (VTE)
- pregnancy-induced hypertension 257
- pregnancy loss
- recurrent 131–44 *see also* recurrent pregnancy loss (RPL)
- pregnancy of unknown location (PUL) 38
- Pregnancy Unique Quantification of Emesis (PUQE) questionnaire 226
- pregnant women *see also* pregnancy(ies)
- self-harm and suicidal ideation among
 - assessment of 381
- premature birth
- defined 397
- prematurity
- corticosteroids for 399–400
- premenopausal women
- endometrial cancer in
 - Lynch syndrome in 186
 - ovarian removal in management of 184–5
 - prognosis of 184–5
- prenatal diagnosis 213–23
- background 213
- case scenario 213
- clinical questions 213–20
- in pregnant women at high risk for aneuploidy
 - amniocentesis 218–19
 - chromosome microarray analysis 219
 - CVS in 218
 - screening methods 213–14
- in pregnant women with low or average risk for aneuploidy
 - screening methods 214–17, **214, 215**
- second trimester genetic ultrasound in 217–18, **217**
- preterm birth *see also* preterm labor
- asthma during pregnancy and 248, **248**
- fetal anomalies and 490
- neonatal morbidity and mortality due to 388, 390
- perinatal morbidity and mortality due to 385, 397
- risk factors for
 - FFN in identifying 387
 - TVS in diagnosis of 386–7
- preterm cesarean birth
- uterine rupture related to 420
- preterm delivery
- after cervical dysplasia
 - risk factors for 192–3
- for pre-eclampsia or placental insufficiency
 - APS and 326–7
- preterm labor 385–95 *see also* preterm birth
- background 385
- case scenarios 385

- causes of 385
- clinical questions 386–92
- management of
 - non-pharmacologic strategies in 392
 - prophylactic antibiotics in 391–2
- patient at high risk for
 - management of 388, **389**
- prevalence of
 - progesterone in 387–8
- risk factors for 386, **386**
 - diagnostic tests in identifying 386–7
 - spontaneous *see* spontaneous preterm labor
 - tocolysis in patients presenting with 391
- preterm labor and delivery
 - in mothers of multiple gestations 469
- preterm premature rupture of membranes (PPROM) 397–406
 - background 397
 - case scenario 397
 - causes of 397
 - complications of 397–8
 - described 397
 - diagnosis of 397–9
 - management of 399–401
 - cervical cerclage and 402
 - corticosteroids in 399–400
 - before fetal viability 401–2
 - following invasive procedures 402
 - HIV and 402
 - HSV and 402
 - in latency period 399
 - magnesium sulfate in 400
 - previable 401–2
 - prophylactic antibiotics in 400
 - tocolysis in 400–1
 - prevalence of 397
 - timing of delivery in 401
- preterm-related complications
 - prevalence of 385
- primary amenorrhea
 - defined 109
 - hypergonadotropic 110–11
 - outflow tract abnormalities resulting in 110
- prochlorperazine
 - in HG management 229
- progesterone
 - in preterm labor and birth prevention 387–8
 - for unexplained RPL 137
- progesterone antagonists
 - for fibroids 68
- progesterone-containing intrauterine devices (IUDs)
 - for HMB 16–18, **17**
- progestin(s)
 - in endometriosis pain management 78
 - in PCOS management 124
- progestogen(s)
 - for HMB 15, 17
 - injected/depot
 - for HMB 18
- prolonged deceleration
 - defined **498, 499**, 500
- physiology of 503
- promethazine
 - in HG management **228, 229**
- prophylactic antibiotics
 - in PPROM management 400
 - in preterm labor management 391–2
- propylthiouracil (PTU)
 - for Graves' disease in pregnancy 309, **310**
- prostaglandins
 - in cervical ripening **531, 532–3**
- protein C deficiency
 - during pregnancy **356, 356, 357**
- protein S deficiency
 - during pregnancy **356, 357, 357**
- prothrombin G20210A (PGM)
 - during pregnancy **356, 356, 357**
- psychiatric disease
 - breastfeeding by women with 380–1
 - in pregnancy 377–84 *see also* depression
 - case scenario 377
- PTU *see* propylthiouracil (PTU)
- PUL *see* pregnancy of unknown location (PUL)
- pulmonary embolism (PE) 559–65
 - case scenario 559–60
 - differential diagnosis of **560, 560**
 - general search strategy 560
 - in pregnant women
 - assessment of pretest probability for 560–2, **564**
 - diagnosis of 357–8, 358
 - maternal deaths related to 355
 - work-up for 560–1, 560–3
 - Pulmonary Embolism Rule-out Criteria (PERC)
 - in assessment of pretest probability for PE during pregnancy 560–2, **564**
- pulmonary regurgitation
 - maternal cardiovascular events related to 276
- pulmonary valve stenosis
 - in pregnancy 274–5
- PUQE questionnaire 226
- pure gonadal dysgenesis
 - amenorrhea related to 111
- pushing
 - during labor **572, 573, 572, 575**
- pyridoxine
 - in HG management 229
- Quadruple Screen 216
- quadraplet(s)
 - Hellin–Zellany rule for 467
- quality metrics
 - in OVD 590
- questions
 - formulation of 3–4, **3**
- RCOG *see* Royal College of Obstetricians and Gynaecologists (RCOG)
- RDS *see* respiratory distress syndrome (RDS)
- recombinant factor VIIa (rFVIIa)
 - in PPH management 547
- recreational drug use

recreational drug use (*continued*)
 preconception care related to 207–8

rectocele repair 104

recurrent early miscarriage
 APS and 326

recurrent pregnancy loss (RPL) 131–44 *see also* miscarriage
 anticoagulant therapy for 138–40, 139
 background 131
 β -hCG for 135–7, 138
 case scenario 131
 causes of 131
 clinical questions 131–41
 defined 131
 diagnostic tests for 132–4
 confounding factors influencing proper assessment of results 137
 EBM in 140–1
 general search strategy 132
 hormone supplementation for 137
 immunotherapy for 139–40
 incidence of 131
 maternal risk factors for 131
 PGS in 140
 pregnancy after
 serum β hCG measurements during 135–6
 prevalence of 131
 prognosis in patient in interval between pregnancies 136
 risk factors for 133–5
 treatment options 136–41, 138, **139, 140**
 unexplained *see* unexplained RPL
 uterine surgery for anomalies related to 137

“refractory obstetric” APS
 during pregnancy
 management of 329–30

regurgitation
 pulmonary
 maternal cardiovascular events related to 276

Reiter’s syndrome 55–6

relaxation therapy
 in preterm labor management 392

renal disease 287–96 *see also* specific types, e.g., chronic kidney disease (CKD)
 case scenario 287
 introduction 287
 in pregnancy
 types of 291–2

renal system
 pregnancy-related adaptations in 287–8, **288**
 acid-base homeostasis 288
 anatomic changes 287
 hemodynamic adaptations 287, **288**
 substrate handling 287–8

renal transplant
 for CKD in pregnancy 293–4

reproductive physiology
 normal 156

respiratory distress syndrome (RDS) 2

restrictive cardiomyopathy 278–9

retained products of conception

induced abortion and 26

review questions
 formulation of 3, **3**
 studies applicable to 3, **3**

Revised Geneva
 in assessment of pretest probability for PE during pregnancy 561, **564**

rFVIIa *see* recombinant factor VIIa (rFVIIa)

Rh status
 in women with EP 42

“rising placenta” 408

robotic-assisted laparoscopy
 for fibroids 69

ROMs *see* rupture of membranes (ROMs)

Royal College of Obstetricians and Gynaecologists (RCOG)
 on diagnostic tests for RPL 132
 on ICP management 483
 on VTE prevention during pregnancy 361

RPL *see* recurrent pregnancy loss (RPL)

rt-tPA *see* thrombolytic therapy with recombinant tissue plasminogen activator (rt-tPA)

rupture of membranes (ROMs)
 preterm premature 397–406 *see also* preterm premature rupture of membranes (PPROM)

sacrocolpopexy
 in pelvic organ prolapse management 103

sacrohysteropexy
 in pelvic organ prolapse management 103–4

sacrospinous ligament suspension
 in pelvic organ prolapse management 103

safety considerations
 OVD-related 587–9

salpingectomy
 in EP management 39

salpingitis
 chronic
 EP and 35

salpingostomy
 in EP management 39–40

“Saving Mothers’ Lives: Confidential Enquiry into Maternal Death” 563

“Scientific Medicine” 2

SCPE Collaborative Group *see* Surveillance of Cerebral Palsy in Europe (SCPE) Collaborative Group

secondary amenorrhea
 defined 109

hypergonadotropic 111

outflow tract abnormalities resulting in 110

second stage of labor
 ACOG on 569
 clinical questions 571–6, 572–4, **573, 575**
 described 571
 length of
 maternal age impact on 576
 maternal outcomes related to 574–5
 neonatal outcome related to 575–6
 obesity effects on 576
 maternal position effects in 572–3, **573**

protocols and practices for 569
 vaginal delivery *vs.* operative delivery related to 573–4, **573, 575**

second trimester
 genetic ultrasound in Trisomy 21 and Trisomy 18 detection 217–18, **217**
 induced abortion in
 methods of 24–5
 screening in
 for pregnant women with low or average risk for aneuploidy **215, 216–17**
 termination methods in **538, 538**
 ultrasound in NTDs detection in 219–20

seizure(s)
 breakthrough
 fetal outcomes related to 316
 medications for
 during pregnancy 206
 teratogenicity of 206
 during pregnancy 315–16
 causes of 316
 EURAP on 315–16
 medications for 206

selective estrogen receptor modulators (SERMs)
 for menopause 158–9
 in PCOS-related infertility management 125

selective progesterone receptor modulators (SPRMs)
 for fibroids 68

selective serotonin reuptake inhibitors (SSRIs)
 during pregnancy 207

self-harm
 by pregnant and postpartum women
 assessment of 381

sentinel lymph node dissection (SLND)
 inguinalfemoral lymph node dissection *vs.*
 in early-stage vulvar cancer detection 175–7, **176**
 in vaginal cancer 177

SERMs *see* selective estrogen receptor modulators (SERMs)

serum β -human chorionic gonadotropin (β -hCG)
 measurements of
 in EP 33
 during pregnancy after RPL 135–6
 for patients with RPL and APS 135–7, **138**
 supplementation with 138
 for unexplained RPL 137, **138**

sexually transmitted infections (STIs)
 LARC methods in women with history of 92
 SF-36 Health Survey 67
 shoulder dystocia
 cesarean delivery in prevention of 460, **460**
 single umbilical artery 488
 single *vs.* double layer closure
 impact on uterine rupture 422
 sinusoidal pattern
 defined **498, 499, 500–1, 501**
 physiology of 503

SLE *see* systemic lupus erythematosus (SLE)

sleep disturbances
 menopause and 157

SLND *see* sentinel lymph node dissection (SLND)

smoking
 contraceptive use and 92
 EP related to 35
 during pregnancy 207
 vulvovaginal cancers related to 174–5

spontaneous abortion
 incidence of 33
 spontaneous delivery
AMTS 576–7, **576**
 background 569
 clinical questions 570–9
 first stage of labor 570–1, **570, 570**
 methods for 569–81
 second stage of labor 571–6, **572–4, 573, 575**
 third stage of labor 576–9, **577, 576, 578**

spontaneous preterm labor
 causes of 388
 defined 388
 diagnosis of 385
 patient at high risk for
 management of 388, **389**
 prevalence of 387–8
 risk factors for 386–7, **386**
 diagnostic tests in identifying 386–7
 TVS in diagnosis of 386–7

SPRMs *see* selective progesterone receptor modulators (SPRMs)

squamous cell carcinoma 165
 vulvar cancer related to 173

SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)

sterilization 89–97
 clinical questions 89–93
 counseling related to 90
 failure of 90
 female 93
 general search strategy 90
 male 93–4
 methods of 93–4
 types of 93–4

sterilization failure
 risk factors for
 counseling on 90

stillbirth(s) 482–3
 assessment of 480–1
 asthma during pregnancy and 248, **248**
 autopsy for 481–2
 care and delivery related to 479–80
 case scenario 479
 defined 479
 fetal anomalies and 490
 fetal demise as 479
 ICP and 483
 introduction 479–80
 pregnancies with prior 483–4
 prevalence of 479
 risk factors for 490
 umbilical cord in 482

Stillbirth Collaboration Network 483

STIs *see* sexually transmitted infections (STIs)

stress urinary incontinence (SUI)
 pelvic organ prolapse without
 management of 104–5

stripping/sweeping membranes
 in post-term pregnancy management 436

stroke
 grading of evidence 319
 during pregnancy 317–19
 background 318
 case scenario 317
 clinical questions 318–19
 management of 318–19
 risk factors for 318
 search strategy 319

ST segment analysis
 in intrapartum FHR monitoring 508

subclinical hypothyroidism
 later development of thyroid disease and 306–7
 in pregnancy
 routine screening for 307
 T4 in 307–8

subfertility
 causes of 145
 defined 145
 unexplained 145–53 *see also* unexplained subfertility

substance abuse
 preconception care related to 207–8

SUI *see* stress urinary incontinence (SUI)

suicidal ideation
 by pregnant and postpartum women
 assessment of 381

superimposed pre-eclampsia on pre-existing hypertension 258–9

Surveillance of Cerebral Palsy in Europe (SCPE) Collaborative
 Group 458

suture(s)
 compression
 in PPH management 549–50, 550

systematic review processes 2–3, 3, 2

systemic devascularization
 in PPH management 549

systemic lupus erythematosus (SLE)
 hydroxychloroquine for 137
 in pregnancy 291–2

T4
 for subclinical hypothyroidism in pregnancy 307–8

tamponade
 balloon
 in PPH management 549

uterine
 in PPH management 548–9

team-oriented care
 for obstetric emergencies 559–68 *see also* obstetric emergencies

TENS *see* transcutaneous electrical nerve stimulation (TENS)

teratogen(s) 206–7, 206
 most common 238, 238

termination of pregnancy 21–32 *see also* induced abortion
 fetal anomalies and 490

term pregnancy
 defined 431
 early 431
 late 431

tetralogy of Fallot (TOF)
 in pregnancy 274

thioamides
 for Graves' disease in pregnancy 309, 310

third stage of labor 576–9, 577, 576, 578
 active *vs.* physiological management of 576–7, 576
 CCT in 576, 577
 defined 569, 576
 described 576
 mean duration of 576
 oxytocin in 576–9, 576, 578 *see also* oxytocin, in AMTSL
 risk of PPH in 576
 TXA in 578
 uterine massage in 576, 577

third trimester
 polyhydramnios in
 ultrasound in detection of 444, 444

thrombocytopenia
 during pregnancy 339–40, 339

thromboembolism
 postpartum
 in obese women 596–7
 venous *see* venous thromboembolism (VTE)

thrombolytic therapy with recombinant tissue plasminogen activator (rt-tPA)
 for stroke during pregnancy 318

thrombophilia(s)
 hereditary *see* hereditary thrombophilias

thromboprophylaxis
 for cesarean delivery in obese women 596–7

thromboprophylaxis bundle
 in VTE prevention 563–4

thrombosis
 APS and 327
 deep vein 355, 357

thymectomy
 in prevention of MG-related complications during pregnancy 321

thyroid disease 303–14 *see also* specific types
 background 303–4, 304
 case scenario 303
 diagnostic criteria for 304
 fetal 310
 later development of
 maternal subclinical hypothyroidism due to 306–7
 in pregnancy
 adverse effects of 303

thyroid function
 pregnancy effects on 303

thyroiditis
 Hashimoto's 303
 postpartum 308

thyroid nodule
 in pregnancy
 assessment of 311

thyroid peroxidase antibodies (TPOAb)

- in pregnancy 305
- thyroid stimulating hormone (TSH)
 - in pregnancy 303–4, **304**
- thyrotoxicosis 308–11 *see also* hyperthyroid disease
 - gestational transient 226
- tocolysis
 - for bleeding placenta previa 409
 - in patients presenting with preterm labor 391
 - in PPROM management 400–1
- “To Err Is Human” 559
- TOF *see* tetralogy of Fallot (TOF)
- TOL *see* trial of labor (TOL)
- toxicity(ies)
 - fetal drug 238, **239**
- toxin(s)
 - environmental
 - preconception care related to 207–8
- TPOAb *see* thyroid peroxidase antibodies (TPOAb)
- tranexamic acid (TXA)
 - in PPH management 547
 - in third stage of labor 578
- transcervical balloon catheters
 - in cervical ripening **531**, 532
- transcutaneous electrical nerve stimulation (TENS)
 - in endometriosis pain management 79
- transplantation
 - renal
 - for CKD in pregnancy 293–4
- transvaginal ultrasound (TVS)
 - in adenomyosis evaluation 78
 - in endometriosis evaluation 77
 - in EP diagnosis 33, 36–8
 - in identifying risk factors for preterm birth 386–7
 - in low-lying placenta diagnosis 408
 - in placenta previa diagnosis 408
- trial of labor (TOL)
 - after previous cesarean birth 419
- Trial of Umbilical and Fetal Flow in Europe (TRUFFLE) 456
- trichomoniasis
 - clinical presentations of 56
 - diagnosis of 57
 - treatment of 58
- “Triple P” procedure 554
- triplet(s)
 - Hellin–Zellany rule for 467
- Trisomy 18
 - in pregnant women at high risk for aneuploidy
 - cfDNA analysis for 213–14
 - in pregnant women with low or average risk for aneuploidy
 - combined first and second trimester screening for 215–16, **215**
 - contingent screening for 216
 - first trimester combined screening for 214–15, **214**
 - second trimester screening for **215**, 216–17
 - second trimester genetic ultrasound in detection of 217–18, **217**
- Trisomy 21
 - in pregnant women at high risk for aneuploidy
 - cfDNA analysis for 213–14
 - in pregnant women with low or average risk for aneuploidy
 - combined first and second trimester screening for 215–16, **215**
 - contingent screening for 216
 - first trimester combined screening for 214–15, **214**
 - second trimester screening for **215**, 216–17
 - second trimester genetic ultrasound in detection of 217–18, **217**
- in pregnant women with low or average risk for aneuploidy
 - combined first and second trimester screening for 215–16, **215**
 - contingent screening for 216
 - first trimester combined screening for 214–15, **214**
 - second trimester screening for **215**, 216–17
 - second trimester genetic ultrasound in detection of 217–18, **217**
- TRUFFLE *see* Trial of Umbilical and Fetal Flow in Europe (TRUFFLE)
- TSH *see* thyroid stimulating hormone (TSH)
- TTTS *see* twin–twin transfusion syndrome (TTTS)
- tubal ligation
 - postpartum 93
- tubal pathology
 - EP related to 34–5
- TVS *see* transvaginal ultrasound (TVS)
- twin(s)
 - ARTs and 467
 - congenital anomalies in 488
 - conjoined 467
 - Hellin–Zellany rule for 467
 - rare occurrence of 467
- twin–twin transfusion syndrome (TTTS) 470–2, 471
- TXA *see* tranexamic acid (TXA)
- UAE *see* uterine artery embolization (UAE)
- UFH *see* unfractionated heparin (UFH)
- UFSQOL Scale *see* Uterine Fibroid Symptom and Quality of Life (UFSQOL) Scale
- ultrasound
 - in appendicitis in pregnancy 371–2, **371**
 - in detection of perinatal outcome related to AF abnormalities 444, **444**
 - in fetal anomalies detection in pregnant patients with polyhydramnios 444–5, **445**
 - in fetal anomalies diagnostic testing 488–9
 - in NTDs detection 219–20
 - in polyhydramnios diagnosis in third trimester 444, **444**
 - second trimester genetic
 - in Trisomy 21 and Trisomy 18 detection 217–18, **217**
 - transvaginal *see* transvaginal ultrasound (TVS)
 - ultrasound-assisted OVD 589–90
 - umbilical artery(ies)
 - single 488
 - umbilical cord
 - in stillbirth 482
 - undetermined/unexplained antepartum hemorrhage (APH)
 - expectant management for 413
 - unexplained infertility 145–53 *see also* unexplained subfertility
 - unexplained RPL
 - aspirin for 139
 - β-hCG for 137, 138
 - cytokine modulation for 140
 - heparins for 139, 139
 - hormone supplementation for 137
 - immunotherapy for 139–40
 - uterine surgery for anomalies of 137
 - unexplained subfertility 145–53

unexplained subfertility (*continued*)
background 145
case scenario 145, 150
clinical questions 145–50
diagnosis of 145
general search strategy 146
management of 145
aromatase inhibitors in 147–8
clomiphene citrate in 146–7
gonadotropins in 147
intra-uterine insemination *vs.* other treatment options in 148–9
IVF *vs.* other treatment options in 149
laparoscopy in 149–50
ovarian stimulation *vs.* other treatment options in 146–8
prevalence of 145
proportion of patients who will conceive spontaneously 146
unfractionated heparin (UFH)
for VTE during pregnancy 358–9
unintended pregnancy
causes of 21
during contraceptive use 91, **91**
unresectable locally advanced vaginal cancer
chemotherapy with radiation therapy *vs.* surgery for 177–8
unresectable locally advanced vulvar cancer
chemotherapy with radiation therapy *vs.* surgery for 177
urinary incontinence 101–6
stress *see* stress urinary incontinence (SUI)
US Evidence-based Practice Centers (EPCs) Program 4–6
USMEC *see* US Medical Eligibility Criteria (USMEC)
US Medical Eligibility Criteria (USMEC)
of CDC 92
US Preventive Services Task Force (USPSTF) 4–6
on pre-eclampsia risk factors 257
USPSTF *see* US Preventive Services Task Force (USPSTF)
uterine anomalies
as risk factor for RPL 134–5
uterine artery embolization (UAE)
in adenomyosis pain management 81
for fibroids 68
in PPH management 550–1
uterine atony
case scenario 545
PPH and 545–51
uterine bleeding
abnormal *see* abnormal uterine bleeding (AUB)
dysfunctional 13
menopause and 157
uterine dehiscence
defined 419
prevalence of 419
uterine fibroids 63–74 *see also* fibroid(s)
Uterine Fibroid Symptom and Quality of Life (UFSQOL) Scale 67
uterine incision type
impact on uterine rupture 422
uterine leiomyomas *see* fibroid(s)
uterine massage
in third stage of labor **576, 577**
uterine perforation
induced abortion and 25–6
uterine prolapse
management of 102
pathology of 102
uterine rupture
antepartum factors influencing 420
clinical questions 420–7
defined 419
mechanism of 419
obstetric history factors influencing 420
prediction of 427
risk factors for 420–2, **423–6**
during TOL after previous cesarean birth
larger fetus effects on 421
maternal age effects on 420–1
uterine tamponade
in PPH management 548–9
uterosacral ligament suspension
in pelvic organ prolapse management 103
uterotonics
in PPH management 546–7, **547**
vaccine(s)
HPV
in CIN prevention 191–2
vacuum aspiration
induced abortion by 23, 24
vacuum delivery
forceps delivery *vs.* 583–4, 585
vacuum extraction
at cesarean delivery
safety considerations 587
vaginal birth
placenta previa and 410
“Vaginal Birth After Cesarean: New Insights” 419
vaginal birth after cesarean (VBAC) delivery 419–30
background 419
case scenario 420
clinical questions 420–7
prevalence of 419
vaginal bleeding
alkaline hematin for 66
fibroids and 65
in first trimester of pregnancy 33
during pregnancy
evaluation of 337–8, **338**
vaginal cancer 173–80 *see also* vulvovaginal cancers
background 173
case scenario 173, 178
causes of 174–5
clinical presentation of 173
deaths related to 173
general search strategy 173
immunosuppression and 174–5, **174**
incidence of 174, **174**
prevalence of 173
SLND in 177
unresectable locally advanced
chemotherapy with radiation therapy *vs.* surgery for 177–8

vaginal closure
in uterine prolapse management 102–3

vaginal delivery
operative 583–91 *see also* operative vaginal delivery (OVD)
operative delivery *vs.*
 factors in second stage of labor determining 573–4, **573, 575**

prior
 uterine rupture related to 420

vaginal pessaries
in pelvic organ prolapse management 102

vaginal spotting
case scenario 33

valacyclovir
for recurrent HSV infection 58, **58**

valproate
during lactation 381

valve(s)
artificial
 during pregnancy 270–1

heart
 during pregnancy 270–1

valvular lesions
causes of 268
during pregnancy
 fetal and neonatal risks associated with 271
 labor and delivery methods related to 271
 management of 269–70
 maternal and obstetric risks associated with 269
 postpartum care 272–3

variable deceleration
defined **498, 499, 500, 501**
physiology of 503

varicella zoster virus (VZV)
in pregnancy 346–8, **347**
 level of evidence 350

vasa previa 413–14
case scenario 413
 clinical questions 413–14
 diagnosis of 413–14
 prediction of 413
 risk factors for 414

vasectomy 93–4

VBAC delivery *see* vaginal birth after cesarean (VBAC) delivery

venous thromboembolism (VTE)
case scenario 355
 deaths due to 560
 imaging modalities for 561, **563**
 introduction 355
 management of
 improvements in 560
 physiologic changes in pregnancy *vs.* 560, **561**
 during pregnancy 355–63
 clinical questions 355–61
 diagnosis of 357–8, 358
 maternal deaths related to 355
 prevention of 359–61, **360**
 risk factors for 355–7, **356, 357**
 treatment of 358–9
 women admitted to hospital 562–5

prevention of
 ACCP on 359, 361
 thromboprophylaxis bundle in 563–4

signs and symptoms of 560, **560**

ventilation/perfusion scanning
for VTE in pregnancy 561, **563**

ventricular septal defects (VSDs)
in pregnancy 274

very low-birthweight (VLBW) infants
 multiple pregnancies and births and 472

vitamin(s)
in FGR management and prevention 457

VLBW *see* very low-birthweight (VLBW)

von Willebrand disease
bleeding in
 management of 338–9, **338**

VSDs *see* ventricular septal defects (VSDs)

VTE *see* venous thromboembolism (VTE)

vulvar cancer 173–80 *see also* vulvovaginal cancers
background 173
case scenario 173, 178
causes of 174–5
clinical presentation of 173
clinical questions 174–8
deaths related to 173
early-stage
 CIL in management of 175–6
 SLND *vs.* inguinofemoral lymph node dissection in detection of 175–7, **176**

general search strategy 173

immunosuppression and 174–5, **174**

incidence of 174, **174**

prevalence of 173

squamous cell carcinoma and 173

symptoms of 173

unresectable locally advanced
 chemotherapy with radiation therapy *vs.* surgery for 177

vulvovaginal cancers
HPV and 174–5

periinvasive and invasive
 immunosuppression and 174–5, **174**

incidence of 174, **174**

VZV *see* varicella zoster virus (VZV)

warfarin
 fetal effects of 238, **239, 238**
 during pregnancy 206
 for VTE during pregnancy 359

wart(s)
 genital 56–9

weight
 fetal
 measurements of 451
 measurements of 451

weight reduction
 in PCOS-related infertility management 125

well-being
 fetal
 in post-term pregnancy 434–5

Wells Criteria
in assessment of pretest probability for PE during pregnancy 561–2, **564**

White classification
for DM in pregnancy 297, **298**

WHO *see* World Health Organization (WHO)

women of reproductive age
CPP in
musculo-skeletal abnormalities with 51

World Health Organization (WHO)
classification system on cardiac disease 267

ZAHARA risk prediction score
for cardiac event during pregnancy 266–7, **266**

Zaki labor duration
maternal age in **571**

zygosity
determination of 467–8
placental arrangement *vs.* 467

zygotic splitting
following ARTs 467